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ABSTRACT 
Introduction 
Universal access to CD4 counts could be improved through easy-to-use point-of-
care CD4 systems such as the PIMA™ Analyzer (PIMA™). Validation studies 
performed in a laboratory and stationary clinic showed promising results. This 
aim of this thesis was to validate the PIMA™ in a mobile clinic in South Africa in 
2010 and to review current literature regarding CD4 technology, with a focus on 
point-of-care technology in the HIV infected individual. 
 
Methods 
Consecutive HIV-positive individuals (both on ART and not on ART) had a 
capillary and/or venous sample analyzed using the PIMA™ and a venous sample 
analyzed externally (Beckman Coulter EPICS XL-MCL flow cytometer (XL-
MCL)). Linear regression and Bland-Altman was used to assess PIMA™ 
performance. The impact of operator, machine, training and time delay to 
laboratory were evaluated. 
 
Results 
The median laboratory CD4 in the 349 participants was 405 cells/µl (IQR 277 – 
600) with CD4 <=200, 201-350 and > 350 cells/µl being 11%, 29% and 60% 
respectively. The mean difference between PIMA™ and XL-MCL CD4 counts 
was -4.5 cells/µl (95%CI -12.4; 3.40) for venous samples (n=325) and 29.7 
cells/µl (95%CI 16.93; 42.49) for capillary samples (n=167). Regression 
coefficients were 0.999 (R2=0.909) and 1.006 (R2=0.882) respectively.  
Misclassification using a 200 cells/µl cutoff was < 3.1% but ±10% with a 350 
cells/µl cutoff for both. 
Multivariable regression analysis, adjusting for operator and training, showed 
machine used and delay to be significant for venous but not capillary samples.  
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Conclusion 
 
The PIMA™ performance in a mobile clinic compared favourably with previous 
studies, identifying most individuals with CD4 counts < 200 cells/ µl. Capillary 
PIMA™ samples gave less reliable estimates than venous samples. Machine 
variability needs further investigation. 
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SCHEMA 
Field evaluation of the PIMA™ Point-of-care CD4 machine in a mobile clinic, 
South Africa 
 
Design:  This study is a cross-sectional study to compare the 
PIMA™ to the Beckman Coulter Epics XL-MCL in 
assessing CD4 counts obtained from HIV-infected 
patients in a mobile clinic setting using both venous 
and capillary samples.  
 
Duration:  Total study duration of approximately 11 months 
 
Sample Size:  A minimum of 165 venous and 165 capillary PIMA™ 
samples  
 
Study participants:  Study participants will consist of HIV positive 
individuals (newly diagnosed, known positive not on 
ART and known positive on ART) identified in the 
mobile clinic who consent to having both PIMA™ and 
laboratory CD4 counts done.  
 
Primary Study Objectives:  1. To assess the agreement between the CD4 count 
obtained when venous or capillary blood was 
analyzed by the PIMA™ Analyzer on a mobile clinic 
and the same sample analyzed by a Beckman                                                  
Coulter EPICS XL-MCL™  
2. To assess the agreement between capillary and 
venous samples using the same individual, same 
operator and same machine. 
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PART I - INTRODUCTION 
1.1 Background 
Point-of-care CD4 testing has recently become available in South Africa. Same 
day, on site availability of CD4 count results enables appropriate post-test 
counseling and, when indicated, immediate referral for antiretroviral treatment. 
This is particularly important in a mobile clinic where it is difficult to 
retrospectively contact clients with their laboratory CD4 result.  
 
The PIMA™ Analyser, the latest point-of-care CD4 machine, is being used by the 
Desmond Tutu HIV Foundation in a mobile clinic setting on the Tutu Tester. It 
enables the determination of absolute counts of CD4 - lymphocytes in whole 
blood without prior sample preparation1 and is suitable for both finger-prick blood 
samples as well as venous blood samples. Full details are described elsewhere. 
1,2
 In-laboratory validation by Glencross  et al. showed good correlation using 
venous samples between the PIMA™ CD4 results and results determined by 
flow cytometry (Slope=0.96, R2= 0.98) on a Beckman Coulter XL. An overall bias 
of -12.02 cells/µl (± 38.65) was noted, with a slight under-estimation of absolute 
CD4 counts by the PIMA™ instrument.3  Excellent correlation of 165 PIMA™ 
capillary samples was found when compared to same day laboratory processing 
of specimens on a Becton Dickinson FACSCalibur in Zimbabwe. The overall bias 
was +7.6 cells/µl (95%CI:-6.5 to +21.8; P=0.72). 1 Greater bias was however 
found when the PIMA™ was evaluated in 2 other clinics in South Africa (D. 
Glencross[debbie.glencross@nhls.ac.za, Lecture, August 4, 2010). 
 
The latter fact, together with our negative experience with another point-of-care 
CD4 technology, the POINTCARE NOW machine, has resulted in our decision to 
do an evaluation of the PIMA™ on our mobile clinic. In addition we feel that a 
validation in a mobile clinic is important in that the setting can be far from ideal: 
the machines are transported over large distances daily, operated on battery 
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power and used in varying environmental temperatures and conditions. It is likely 
that similar conditions will be encountered at sites where the PIMA™ will be most 
useful. 
During the first month of using the machine all clients testing at the mobile clinic 
had both a laboratory and PIMA™ CD4 count done. Preliminary findings 
comparing PIMA™ results with CD4 count results determined on a Beckman 
Coulter Epics XL-MCL (XL-MCL) (Togatainer, Toga laboratories, Gugulethu) 
(n=63) showed good correlation (Slope=0. 91, R2= 0.90) (Figure 1). 
 
Figure 1: Comparison of point-of-care CD4 count results using the PIMA™ 
system with laboratory CD4 count results performed on the Beckman Coulter 
EPICS XL-MCL. 
 
 
Staff also performed both dual capillary and venous samples on a small number 
of patients (n=12) to ascertain whether these methods give different results. A 
mean difference of 31.09 cells/µl (CI -16.42; 80.24) was found between capillary 
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and venous samples. This finding warrants further investigation. Ethical approval 
for this will be obtained as a sub-study on: Cross-Sectional Survey of HIV 
infection and CD4 counts in Masiphumelele township (REC REF 262/2010). 
1.2 Aims and Objectives 
Aim: 
 
To perform a field evaluation of the PIMA™ CD4 Analyzer in a mobile clinic 
setting in South Africa 
 
Primary Objectives: 
 
1. To assess the agreement between the CD4 count obtained when venous 
or capillary blood was analyzed by the PIMA™ Analyzer on a mobile clinic 
and the same sample analyzed by a Beckman Coulter EPICS XL-MCL™ 
2. To assess the agreement between capillary and venous samples using 
the same individual, same operator and same machine 
 
Secondary Objectives: 
 
1. To assess factors associated with greater or lesser agreement: machine, 
user and the impact of training sessions 
2. To calculate misclassification around the current CD4 based cutoffs of 200 
and 350 cells/µl as used in South Africa 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
7 
 
PART II - METHODS 
2.1 Study design 
Cross-sectional study  
2.2 Study setting 
The Tutu Tester is a nurse run, counsellor supported mobile screening clinic run 
by the Desmond Tutu HIV Foundation. It is a fully mobile vehicle with 3 rooms 
and also has tents which can be pitched to provide additional space. It operates 
5 days a week mainly in underserviced peri-urban areas in greater Cape Town 
and rotates through sites such as township shopping centres, taxi ranks and 
stations, as well as on the road side. This service is not formally advertised and 
hence attracts ambulatory clients who spontaneously access HIV testing. This 
client initiated HIV testing is offered in combination with screening for other 
chronic conditions such as hypertension, diabetes and obesity in an attempt to 
normalize testing and is performed according to the latest Western Cape HIV 
testing guidelines4. 
Medical history, physical examination findings and risk reduction information is 
recorded on a client form (Appendix 1) 
 
The standard of care for all Tutu tester clients is that if they test positive on their 
first HIV test, staff will obtain a second blood sample (either capillary, venous or 
both if necessary) and perform a confirmatory HIV test, syphilis test and a CD4 
count. The latter is either a PIMA™ Point-of-care CD4 count (Alere, Waltham, 
USA) and/or laboratory CD4 performed at the Togatainer (TOGA Laboratories, 
Gugulethu). Clinical staging is performed and a pregnancy test is done if the 
client is female. 
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2.3 Subjects 
2.3.1 Study population 
Study participants will consist of HIV positive individuals (newly diagnosed, 
known positive not on ART and known positive on ART) identified in the mobile 
clinic that consent to having both PIMA™ and laboratory CD4 counts done.  
They include: 
1. Those from the preliminary field study  
2. All HIV positive individuals who consent to taking part in the “Active 
Tuberculosis Case Finding in individuals accessing a mobile voluntary 
counselling and testing service” (REC REF: 507/2008) (Appendix 2). They 
will have a PIMA™ CD4 count done on the Tutu Tester as well as a 
laboratory CD4 count as part of study procedures.  
3. Those who consent to taking part in the Cross-Sectional Survey of HIV 
infection and CD4 counts in Masiphumelele township (REC REF 
262/2010) and give additional consent for providing both venous and 
capillary PIMA™ samples (Appendix 3: sub-study 2)  
Inclusion criteria: 
1. HIV–infected individuals 
2. Age 18 years and older 
3. Able and willing to provide the relevant informed consent 
Exclusion criteria: 
1. Individuals with indeterminate HIV results at the time of testing and who 
had CD4 counts done but are PCR negative  
2. Age less than 18 years old 
3. Unable to provide informed consent 
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2.3.2 Sampling strategy and size 
Consecutive sampling will be used to select patients.  
Our sample size calculation is based on the initial NHLS data for 50 patients with 
venous PIMA samples where the mean difference was -12.02 (+-38.65) cells/µl 
between PIMA and laboratory samples. Our hypothesis is that our mean 
difference will be 0. The estimated sample size for a one-sample comparison of 
mean to the hypothesized value of 0 is 109 using a power of 0.90 and a 
significance level of 0.05. 
However a target size of 165 samples will be set for both the venous and 
capillary arms so that our sample is at least as large as the literature currently 
published1.  
 
For the dual venous and capillary PIMA sample group we will however aim to get 
a sample size of 109 to limit study costs.  
2.4 Study procedures 
PIMA™ CD4 testing 
All staff operating the PIMA™ CD4 Analyzer will be trained by an Alere 
Healthcare representative on the use of the PIMA™ device and the correct 
sample collection techniques.  
Materials will be stored and daily controls will be run according to the 
manufacturer’s instructions2,5,6. The required 25µl of blood will be collected into a 
PIMA™ cartridge from either a finger prick or venous sample or both. The 
cartridge will capped and then inserted immediately into the Analyzer. 
Nurses will to use a 1.8mm blade lancet for the capillary samples. Venous blood 
will be collected by phlebotomy in a 4ml EDTA tube and transferred to a PIMA™ 
cassette by means of a pipette. The sample will be run on the PIMA™ Analyzer 
available for use on the mobile clinic. 
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The nurse will document if the sample is venous or capillary. The time, date, 
operator and machine number are all reflected on the result printout.  
Where dual samples are taken, the nursing will first do a PIMA™ CD4 test using 
capillary blood and then using the venous sample. The nurse who takes the 
venous samples must be responsible for transferring the venous blood to the 
PIMA™ cartridge. The samples must be run on the same machine. 
 
Laboratory testing 
Venous blood collected in a 4ml EDTA tube will be kept at room temperature and 
transported to the Togatainer on the next working day. The specimens will be 
analyzed using their standardized protocols on a Beckman Coulter EPICS XL-
MCL™ (XL-MCL) flow cytometer. Both internal and external quality control 
procedures are in place at the laboratory. Laboratory staff will be blinded to the 
PIMA™ results. 
Results stating the date of receipt at the laboratory and the CD4+ T-lymphocytes 
and %CD4 (percentage of total lymphocytes) will be emailed to the investigator.  
 
CD4 results 
 
All HIV positive clients will be given their PIMA™ results at the time of their Tutu 
Tester visit and encouraged to attend clinics for either comprehensive HIV care 
(PIMA™ CD4 count > 201 cells/µl) or to start ART if eligible (PIMA™ CD4 count 
≤ 200 cells/µl or WHO stage 4). Where dual samples were taken clients will be 
asked to wait for, and receive, their capillary result. Waiting for the venous 
PIMA™ result will be optional. 
 
The client will be contacted by telephone with their laboratory CD4 result (usually 
within 72 hours) and, where applicable, their venous PIMA™ CD4 count result if 
permission to do this was given (see section 2.5 Data collection). Alternatively 
they can collect their result from the Tutu Tester.  
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The PIMA™ and laboratory results could differ in a way that would result in a 
change of the client’s management. If we are unable to contact the client 
telephonically, a home visit will be attempted if permission was given to do so, to 
give the client their result. An additional sample for laboratory CD4 testing will be 
taken where possible to assist in the further management of the client.   
2.5 Data Collection 
Routine data is collected on all Tutu Tester clients (Appendix 1). CD4 results will 
be recorded on the study specific data collection form (Appendix 4). 
 
HIV positive clients will be requested to give their name and surname and 
contact details (see attached client details form- appendix 5). This specifies if, 
and how, we can contact the client in order to provide them with their laboratory 
CD4 count result. The client is asked to verify that the details are correct by 
signing the form. 
 2.6 Data management 
All forms are returned to the Tutu Tester office in the evening and locked in the 
data room. Forms, tog ther with laboratory results, belonging to HIV positive 
clients are kept in a locked cupboard in the data room with only relevant staff 
members having access to the files.  All Tutu Tester staff is required to sign a 
confidentiality agreement when they start working on the project 
 
Data is entered anonymously into an Access database designed for the study. 
Data entry is performed by designated staff members of the Desmond Tutu HIV 
Foundation. The database is password protected with only limited designated 
staff having access to them. The database is stored on a data server located at 
the DTHC which is backed up daily. Queries are run for inconsistencies and data 
is corrected continuously.  
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Data required for the purpose of this analysis will be obtained by running a query 
on the database. 
2.7 Staff training 
All nursing staff are trained in the correct methodology for rapid HIV testing, the 
use of the PIMA™ Analyzer and Good Clinical Practice.  
2.8 Biohazard containment 
Study staff will follow universal precautions when handling the specimens. This 
includes wearing of gloves. 
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PART III – DATA ANALYSIS 
Statistical analysis will be performed using STATA (Version 11.0, College 
Station, Texas, USA).  
Data will be explored via simple proportions, medians, means, cross-tabulations 
and chi square tests. A Wilcoxon Signed Tank test will be used to calculate 
differences in median results between PIMA™ CD4 and laboratory CD4 results. 
 
The sensitivity and specificity for the PIMA™ CD4 results, as well as and Kappa 
statistics, will be calculated using laboratory cut-offs of 200 and 350 cells/µl. 
The data will be analyzed using scatter plots and the correlation co-efficient will 
be calculated. We will then perform a linear regression analysis and attempt to 
predict factors impacting on the performance of the PIMA™. The factors of 
interest are operator, machine and training. 
Bland-Altman analysis will be done to determine the systematic bias of the 
PIMA™ relative to the XL-MCL. 
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PART IV - ETHICS AND COMMUNICATION 
4.1 Ethical Considerations 
Ethics has already been obtained for reporting of programmatic data from the 
Tutu Tester (Appendix 6). 
All the procedures described here will be reviewed and approved by the 
University of Cape Town Research Ethics Committee. This study also adheres to 
the declaration of Helsinki 2008. 
 
a.   Participant Withdrawal 
Study participation may be discontinued for either of the following reasons: 
• The participant withdraws her consent.  Participants may withdraw from study 
participation at any time, for any reason. This will in no way alter their 
treatment at the Tutu Tester. 
• The nurse determines it to be in the best interest of the subject for a medical 
reason or the study for a technical reason. 
b. Informed Consent 
Informed consent will be obtained from all study participants. This will be verbal 
in routine Tutu Tester clients as well as for patients taking part in the active TB 
case finding study. Written consent will be obtained by one of the Tutu Tester 
nurses where both a venous PIMA™ and capillary PIMA™ and laboratory 
sample are required (Appendix 7). The rationale of the study, procedural details 
and investigational goals will be explained to each participant together with 
potential risks and benefits via the informed consent form. 
Consent forms will be available in English and Xhosa. All translations will be 
checked to verify content. 
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c.   Risks and Discomforts 
 
• Capillary and Venous blood samples are invasive and might cause some 
discomfort. All nurses are trained in finger-prick sampling and venous 
blood sampling. This study will in no way alter the clinical management of 
participating patients. 
 
d.   Benefits 
• The direct benefit to the participant for taking part in this study is that they will 
be able to obtain have confirmation of their CD4 count both immediately and 
with a follow-up telephone call for their laboratory result. 
• An indirect benefit would be the opportunity to help researchers find out if 
there is better correlation with one method versus the other to determine best 
practice on the Tutu Tester. 
 
e.   Confidentiality 
Every effort will be put in place to maintain participant’s confidentiality. The staff 
will conduct follow-ups in accordance with the Tutu Tester SOP for follow-ups. 
Confidential data will be managed as discussed in section 2.5 above.  
4.2 Dissemination of results 
An abstract will be submitted in October 2010 for the CROI conference in 
February 2011. A manuscript entitled: “Field evaluation of the PIMA™ Point-of-
care Cd4 machine in a mobile clinic, South Africa” will be completed by Month 
11. Results and feedback will also be made available to Alere Healthcare on an 
ongoing basis as well as to our funders. 
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PART V - LOGISTICS 
  
Month 
  1 2 3 4 5 6 7 8 9 10 11 
Mar 
2010 
April 
2010 
May 
2010 
June 
2010 
July 
2010 
Aug 
2010 
Sep 
2010 
Oct 
2010 
Nov 
2010 
Dec 
2010  
Jan 
2011 
1) Data collection & entry 
Routine Tutu 
Tester Clients 
                      
Active TB 
Case Finding 
study 
                      
Dual samples 
from Cross-
Sectional 
Survey  
                      
2) Data 
analysis 
                      
3) Manuscripts 
CROI abstract                       
Manuscript                       
 
PART VI - BUDGET 
The cost of the PIMA™ CD4 and laboratory tests will be covered as Tutu Tester 
operating costs. 
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Background 
 
South Africa continues to be home to the world’s largest population of people 
living with Human Immunodeficiency virus (HIV)1,2 3 . Despite having more than 
971 000 people on antiretroviral therapy (ART) in October 2009 4, the ART 
coverage in this large, continually expanding programme is still incomplete and 
was estimated to be only around 28-40% in 20085 6.  
 
Studies from South Africa have show that only 55-90% of individuals have their 
CD4 count done after testing HIV positive despite the time frames being 
generous in these studies and ranging from two to six months7-9. Furthermore 
only 46-65% of individuals receive their CD4 count results7-10.  
 
This is concerning as the enumeration of absolute numbers of CD4-positive T- 
lymphocytes plays an essential part in the monitoring of those with HIV:  
determining when ART is needed, monitoring the effectiveness of ART and 
indicating possible treatment failure. Moreover the current South African 
treatment initiation guidelines11 are CD4 based.  
 
This high attrition rate between being tested and receiving a CD4 count result 
means that individuals eligible for ART either have lengthy delays before ART 
initiation or are lost to care. If insufficient emphasis was placed by health-care 
workers on the importance of knowing the CD4 count or the benefit of remaining 
in care despite feeling otherwise well, individuals may not understand the 
importance of returning for their result. Long waiting times due to high caseload 
may also be a reason why individuals fail to return for their results and 
subsequent appointments10.   
 
Reductions in treatment delays would improve morbidity and mortality 12-15, 
including reducing HIV-associated Tuberculosis (TB)16 and reducing transmission 
of HIV from mother to child 17,18.  In this light the latest WHO guidelines2 
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recommend earlier diagnosis through expanded testing programmes and ART 
initiation for all HIV-infected individuals with a CD4 count of ≤350 cells/µl. The 
guidelines reiterate that the lack of laboratory monitoring should not be a barrier 
to initiating ART and those with WHO clinical stage 3 or 4 should be initiated on 
ART if CD4 testing is not available. The WHO guidelines also encourage CD4 
testing in those with WHO clinical stage 1 and 2 to timeously identify those 
needing ART2. 
 
Furthermore a recent cost-effectiveness analysis 19 recommended that countries 
with very limited resources and still only one line of ART available should 
prioritize access to CD4 count monitoring and ART initiation at CD4 ≤ 350 cells/µl 
to offer the best survival outcomes. 
 
The anticipated escalation in numbers of people in South Africa requiring CD4 
counts as more individuals are found to be HIV-positive following the launch of 
the National HIV testing campaign, and current up scaling of the ART 
programme, may overburden the current National Health Laboratory Services 
(NHLS).  Alternative reliable methods of performing CD4 counts need to be 
evaluated to improve access to, and reduce overall costs of performing CD4 
assays especially in more outlying or lower burden areas.20  
 
The objective of this literature review is to ascertain methods in which the ever 
growing need for CD4 counts for HIV-infected individuals can be addressed with 
a special focus on the benefits of point-of-care technology. 
 
Literature search strategy: inclusion and exclusion criteria 
A computerized search of electronic databases was performed to find available 
literature on Point-of -Care CD4 technology.  
The search terms used for Medline were: (CD4 Lymphocyte Count [MESH] or 
CD4-positive T-lymphocytes [MESH]) AND (Point-of-care systems [MESH] or 
POC (text term) or point*of*care (text term)). This search was combined with a 
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search using: (CD4 Lymphocyte Count [MESH] or CD4-positive T-lymphocytes 
[MESH]) AND (HIV infections [MESH]) AND (Flow cytometry [MESH] or image 
cytometry [MESH] or flow cytometry (text term)). The search was restricted to 
humans and papers published in the last 10 years (2001 through to January 
2011) as point-of-care technology is a new development in this field. Only papers 
published in English were reviewed. The 572 citations were screened by title to 
capture potentially suitable publications.  The abstracts of the suitable papers 
were then reviewed and the full text of suitable original papers and scientific 
letters was then obtained.  
Reference lists of primary studies, reviews and editorials identified by the above 
methods were searched for additional articles. Experts in the field were contacted 
for additional literature, including abstracts from conferences. The manufacturers 
of the PIMA™ machine were able to provide additional evaluations of the 
machine but unfortunately none of these have been published to date and so 
were not used. 
 
The current situation 
Universal access to CD4 count monitoring, in South Africa and other resource-
limited countries, is hindered by centralized laboratory services, the challenges of 
transporting samples to these laboratories, cost and delays in receiving results21. 
 
Options to meet the need for improved access to CD4 count monitoring include 
finding alternatives to CD4 counts, decentralizing or addressing challenges faced 
by laboratories and point-of-care CD4 counts. These will be discussed in detail 
below. 
 
Various studies have evaluated alternative methods to CD4 counts using 
laboratory measures which may be more readily available including total 
lymphocyte counts (TLC) 22; combining clinical staging with TLC, or combining 
TLC with haemoglobin levels, platelet counts and body mass index 22-27. These 
have given conflicting results and are no longer recommended2,28.  
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Clinical assessments alone may miss individuals who appear clinically well yet 
are severely immune-compromised29. Relying solely on clinical staging according 
to WHO criteria requires that patients be seen by clinicians or experienced and 
trained nursing staff30. Access to this cadre of healthcare personnel is often an 
issue in exactly those areas where access to CD4 counts is also lacking31,32. 
POC CD4 counts would enable task shifting for HIV care and treatment to less 
skilled nurses and potential other health workers30. 
 
Currently flow cytometry remains the accepted gold standard for performing CD4 
counts20,33. It is an established laboratory technique that was available even prior 
to the HIV epidemic to confirm and monitor immune suppression34. Flow 
cytometry simultaneously measures and analyses multiple physical 
characteristics of cells as they flow in a fluid stream through a light beam 
measuring the cell’s relative size, granularity and fluorescence intensity. Lasers 
are used to excite fluorescent antibody probes specific for CD4 T-lymphocytes.35 
A simplified single platform (SP) PanLeucogated (PLG) CD4 methodology is now 
most commonly used in South Africa36.  
Most commercially available flow cytometers have automated procedures 
allowing many specimens to be tested simultaneously37 38. The high output flow 
cytometers, performing from 250 to 350 samples per day38, include the 
FACSCalibur (Becton Dickinson, Franklin Lakes, NJ)39, EPICS XL-
MCL(Beckman Coulter, Brea, CA)40 and Cyflow SL-3 (Partec, Mϋnster, 
Germany)41. Low-intermediate throughput machines can perform 30 – 100 tests 
per day38 and includes the FACSCount (Becton Dickinson, Franklin Lakes, NJ)39, 
Cyflow Counter (Partec, Mϋnster, Germany)41, Easycyte (Millipore, Billerica, MA) 
(previously EasyCD4, Guava Technologies, Hayward, CA) 42and PointCare Now 
(PointCare Technologies, Malborough, MA)43.  
In addition non-flow cytometry techniques can be employed in laboratories. 
Existing non-flow cytometry techniques are typically manual or semi-manual 
assays and perform less than 50 tests per day38. Manual magnetic isolation of 
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cells is done on a haematology analyzer with Sysmex Dynabeads (Sysmex)44 or 
using a microscope count with Dynabeads (Invitrogen, previously Dynal SA)45. 
Manual antibody-based identification of cells and microscope counts is done with 
Coulter®Manual CD4 count kit (previously Cytosphere) (Beckman-Coulter)46 
 
For all the above-mentioned laboratory-based CD4 testing techniques venous 
samples need to be obtained by phlebotomy. This requires the attending health 
care provider to have the necessary skills to do so which remains a limiting factor 
in many health care facilities. 
  
Further issues with laboratory testing include: 
• Delays in samples reaching the laboratory causes sample aging.   
Aging of blood samples collected in a K2EDTA tube causes changes in all 
white blood cells which affect the light scatter properties of the cells. This 
makes distinguishing monocytes from lymphocytes difficult in routine flow 
cytometry. Automated gating algorithms usually fail to identify the relevant 
populations and the technologist thus has to manually gate these 
samples. This can be challenging and, if monocytes are counted as T-
helper cells, it could lead to an overestimation of the CD4 count 
(W.Pretorius [willem.pretorius@alere.com], email, May 16, 2011).   
Another factor that could influence the CD4 count in aged specimens is 
ongoing spontaneous apoptosis which appears to occur more in samples 
from patients with low CD4 Counts 47.   
Unsatisfactory storage conditions of samples (temperatures more than 25 
degrees Celsius), especially when transporting specimens from remote 
areas to a central laboratory, can also accelerate these changes. 
Because there are multiple factors at play it is difficult to predict if aged 
specimens will over or underestimate the CD4 count. In order to get 
accurate CD4 counts specimens should be analysed no later than 48 
hours after the specimen was collected. 
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•  Adequate human resources are often lacking in resource-limited 
settings31,32 yet skilled and trained personnel are required to operate the 
machines available in the laboratories.  
• Incorrect pipetting techniques cause errors in absolute cell counting 
especially when sample preparation is required. Cap piercing technology 
is not employed by all machines20.  
• Flow cytometers such as FACSCount require liquid format reagents48 . 
Cold-chain transportation and refrigeration are needed to maintain 
reagent integrity. Whilst this is not an issue in developed countries, 
resource-limited rural settings are faced with unreliable cold-chain 
transportation and inconsistent power supplies. Maintaining a cold chain 
adds additional cost to an already expensive test especially for remote 
laboratories with low patient flow.  
• A lack of maintenance of the machines and hence non-functioning 
machines  as well as procurement issues for reagents30 are of concern 
especially for dedicated flow cytometers at remote sites.  
 
Solutions 
Suggestions for improving access to CD4 count results include: 
• Reduced turnaround times for results by increasing laboratory capacity 
• Making CD4 count results more broadly available such that results could 
be accessed at clinic-level rather than at hospital level where the patient 
may have been seen initially10. This would mean that patients would not  
need to make costly trips to obtain their results30. 
  
Suggestions for prolonging sample stability include: 
• Transfix, a blood stabilizing compound 49  
• BD CD4 stabilization tubes (ST [Vacutainer CD4 stabilization blood 
collection tubes; Becton Dickinson Vacutainer Systems, Franklin Lakes, 
NJ]). 50 
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Suggestions for maintaining reagent integrity:  
Liquid reagents in remote laboratories could be replaced with dried reagent kits 
such as Rea T Count (Reametrix, Bangalore, India)48. It was found to be a 
suitable replacement for liquid reagents normally used with the FACSCount if 
adequate mixing of the dry reagent occurs48.  
 
Researchers worldwide are thus striving towards developing a point-of-care 
(POC) method for performing CD4 counts.  
 
Point-of-care testing 
POC testing has been defined as “any investigation carried out in a clinical 
setting or a patient’s home for which the result is available without reference to a 
laboratory and perhaps rapidly enough to affect immediate patient 
management”51 
 
The ideal characteristics of a universal POC CD4 test for low-income countries 
are: (i) It should be simple to use20,30,38 so that it can be performed with minimal 
training. This could allow for task-shifting to less skilled health personnel.(ii) It 
should be able to be performed using non-venous blood30: This means that 
phlebotomy skills are not required to perform the test. (iii) The result should be 
easy to read and interpret 30. (iv) Any equipment required should be robust 20,52,53 
so that it can withstand a wide array of environmental conditions such as hot, dry, 
dusty or humid climates. (v) It should be reliable30 and give precise and 
reproducible results. This reduces the need to repeat tests and decreases the 
cost per patient. (vi) The test kit or reagents should not be cold chain dependent 
and should be able to withstand hot climates of up to 40 C20,30,34,38,52 (vii) The test 
kits should have a long shelf life20,53 of up to 15months30 (viii) Processing of the 
test should be short; about 10 minutes has been recommended.30. (ix) It should 
be affordable; a cost of $1-2 20,30 would be acceptable to most low-income 
countries.   (x) Bio-hazardous waste generated should be minimal30,52. (xi) There 
should be some form of quality control and ideally the test should be suitable for 
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an external quality assurance programme30,34,38,52 such as QASI and  AFREQAS. 
(xii) The maintenance for any machinery should be minimal as access to routine 
technological maintenance can be difficult38,52,53. In addition replacement units 
should be readily available38. (xiii) It should also not rely on basic services such 
as a consistent electricity supply 20,52,53 or clean water20. 
The availability of point-of-care (POC) CD4 technology with characteristics such 
as those described above should increase the number of CD4 counts done as 
well as the number of individuals receiving their results, especially in mobile clinic 
settings or when transport costs and access to health care facilities (both through 
user fees and availability of staff) are barriers to returning to the facility. 30,54,55 
When POC HIV testing was newly introduced, it was shown that 99% of 
individuals testing at mobile clinics in Zimbabwe chose same day HIV results 
over receiving their results at a future date at their local clinic.56 The uptake of 
POC CD4 is unlikely to be less than this.  
 
Ideally one would offer HIV testing in combination with POC CD4 testing30. This 
would enable directed post-test counseling, based on the CD4 result, and would 
enable immediate referral for ART initiation. POC CD4 testing could potentially 
increase both the number of individuals remaining in HIV wellness programmes 
as well as the number of people initiating ART. 
 
Concerns regarding POC CD4 testing 
Concerns around providing POC CD4 tests include: 
• The task of performing the POC CD4 test may become the responsibility 
of the nursing staff who typically already face high patient volumes and 
high workloads.38 This change in job description may lead to low levels of 
motivation38 and the increased level of responsibility may require a 
suitable salary increase32.  
•  Strict quality control procedures need to be in place to ensure that test 
are being performed correctly such that results produced are accurate 
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• True POC testing does not offer economy of scale. Consumable and 
labour costs, which make up the bulk of the overall cost of performing a 
POC test do not change regardless of how many tests are performed37,38. 
This is in contrast to laboratory testing, where the most significant cost is 
the fixed cost of running the equipment whilst the cost of consumables 
remains insignificant37 
• Tests may be done unnecessarily due to the ease of having the test 
results available during the time-frame of the consultation 
.   
Current options for CD4 testing in mobile clinics in South Africa 
Although several such innovative means of assessing CD4 counts using non-flow 
cytometry have been published over the past few years, they have either not 
been commercialized or not been rolled out on a large scale 21,35,57-67.                                                                                                                            
 
Three options were considered for use in our mobile clinic which is in a primary 
care setting and where nurses, rather than laboratory technicians, perform the 
CD4 counts. They were the Easycyte (Millipore, Billerica, MA) (previously 
EasyCD4, Guava Technologies, Hayward, CA) 42, the PointCare Now (PointCare 
Technologies, Malborough, MA)43 and the PIMA™ Analyser (Alere, Waltham, 
USA).  
 
The Guava Easy CD4 uses microcapillary single flow cytometry. This eliminates 
the need for sheath fluid and thus requires smaller samples and fewer reagents, 
with minimal waste. Several evaluations have found that it compares well with 
flow cytometry both in laboratory and clinical settings52,68-70. Although it is 
compact and ideally sized for small laboratories, it is not suitable for our mobile 
clinic setting. The sample requires pipetting and further preparation by a 
dedicated nurse, detracting from patient care. Furthermore the knocks sustained 
when driving the mobile as well as the vibrations as people step on and off the 
mobile are likely to cause misalignment of the laser technology53.  
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No published literature is available on the Pointcare NOW43. This compact and 
portable modified flow cytometer uses heat-stable colloidal gold-labelled 
reagents instead of monoclonal antibodies and fluorescence. This eliminates the 
need for fluorescence signal filter detectors 20 and should make it less likely to 
have optical alignment problems. Unpublished data from our mobile clinic 
however showed that results were poor and use of the machine was 
discontinued. 
 
The PIMA™ Analyser (ALERE, Waltham, USA) is the only commercially 
available true POC CD4 machine in South Africa. It is suitable for performing 
POC CD4 counts using both finger-prick (capillary) and venous blood samples. 
CD4-lymphocytes are labeled with fluorescing monoclonal antibody labels which 
are detected using image cytometry71,72. It can be readily transported to site in 
the carrier bag provided, can be battery operated and has no liquid bio-
hazardous waste. In addition it is easy to operate, requires no specific technical 
skills to do so and requires little maintenance. The cartridges are also heat 
stable.  
 
Recent evaluations show good correlation between PIMA™ CD4 results and 
laboratory CD4 counts73-75. In-laboratory validation75 at the National Health 
Laboratory Service (NHLS) in Johannesburg between PIMA™ CD4 results from 
venous samples and results determined by flow cytometry based PLG/CD4 
showed a slight under-estimation of absolute CD4 counts by the PIMA™ 
Analyzer (Table 1). Capillary samples run on the PIMA™ Analyzer in Zimbabwe 
showed a slight over-estimation of absolute CD4 counts when compared to same 
day laboratory processing of venous blood specimens from the same individual 73  
(Table 1).  
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Table 1. Comparison of CD4 results from evaluations of the PIMA™ Analyzer  
 
 
N PIMA 
sample 
type 
Laboratory 
CD4 range 
Bias Slope R2 
Coetzee al.75  100 
 
Venous 3 - 1332 -16.86 ± 36.7 
 
0.913 ± 
0.013 
0.981 
Mtapuri-
Zinyowera et 
al73 
165 Capillary 1 - 1297 +7.6 
(CI -6.6 ; 21.8)  
Not done Not 
done  
 
 
Variability of CD4 counts results 
 
Various techniques for determining CD4 counts are currently available as 
described above, however they vary in accuracy and reproducibility as no 
definitive “gold standard” for CD4 counts exists. In addition pphysiological intra-
subject factors can lead to variability in CD4 count measurements. CD4 counts 
vary by time of day76,77, as well as by season, and may also be influenced by 
acute and chronic infections78. The CD4 count can drop temporarily during 
pregnancy, infections (e.g. Tuberculosis) and during other systemic conditions78. 
Treatment with corticosteroids can also cause a significant drop in the CD4 
count78. 
 
Typically the CD4 cell count decreases progressively over time  and decreases 
by 50-75 cells/µl per year in the absence of ARVs78. The CD4 rises after ART 
initiation: typically by 50 cells/µl in the first weeks, and then 50-100 cells/µl if 
there is good viral suppression78. 
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Opportunistic infections and well as the risk of developing immune reconstitution 
syndrome become more common with declining CD4 counts but are uncommon 
with CD4 counts over 500 cells/µl and most common below 200, with those 
below 100 and below 50 at increasing risk78. Variations in CD4 count in those 
with counts greater than 500 have less clinical impact. However, the lower the 
CD4 count, the more important it is for the CD4 count to be accurate, regardless 
of the technology used.  
 
Identification of gaps for further research 
To date there is a paucity of data from sites such as mobile clinics where the 
PIMA™ CD4 analyzer is most likely to be used with the greatest benefit. Mobile 
clinics are different to standard laboratory environments and can be far from 
ideal: the machines are transported over large distances daily, operated on 
battery power and used in varying temperatures and conditions.  
It is also unclear as to which method of blood collection for CD4 counts is most 
suitable as there is no data comparing venous to capillary PIMA™ samples taken 
from the same individual. 
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This will be formatted for submission to JAIDS. Instructions for authors are 
available in Appendix 8. The Authorship Responsibility, Financial Disclosure, and 
Copyright Transfer form is also included.  
Supplementary figures and tables are in Appendix 9. 
The machines were donated by Alere Healthcare, but Alere had no part in 
design, conduct or analysis of the study.   
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Abstract 
 
Introduction 
Universal access to CD4 counts could be improved through easy-to-use point-of-
care CD4 systems such as the PIMA™ Analyzer (PIMA™). Validation studies 
performed in a laboratory and stationary clinic showed promising results. This 
study aimed to validate the PIMA™ in a mobile clinic in South Africa in 2010.  
 
Methods 
Consecutive HIV-positive individuals (both on ART and not on ART) had a 
capillary and/or venous sample analyzed using the PIMA™ and a venous sample 
analyzed externally (Beckman Coulter EPICS XL-MCL flow cytometer (XL-
MCL)). Linear regression and Bland-Altman was used to assess PIMA™ 
performance. The impact of operator, machine, training and time delay to 
laboratory were evaluated. 
 
Results 
The median laboratory CD4 in the 349 participants was 405 cells/µl (IQR 277 – 
600) with CD4 <=200, 201-350 and > 350 cells/µl being 11%, 29% and 60% 
respectively. The mean difference between PIMA™ and XL-MCL CD4 counts 
was -4.5 cells/µl (95%CI -12.4; 3.40) for venous samples (n=325) and 29.7 
cells/µl (95%CI 16.93; 42.49) for capillary samples (n=167). Regression 
coefficients were 0.999 (R2=0.909) and 1.006 (R2=0.882) respectively.  
 
Misclassification using a 200 cells/µl cutoff was < 3.1% but ±10% with a 350 
cells/µl cutoff for both. 
Multivariable regression analysis, adjusting for operator and training, showed 
machine used and delay to be significant for venous but not capillary samples.  
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Conclusion 
 
The PIMA™ performance in a mobile clinic compared favourably with previous 
studies, identifying most individuals with CD4 counts < 200 cells/ µl. Capillary 
PIMA™ samples gave less reliable estimates than venous samples. Machine 
variability needs further investigation. 
 
Key words: CD4 lymphocyte count, point-of-care, mobile clinic, HIV, PIMA™ 
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Introduction 
 
South Africa is home to the world’s largest population of people living with 
Human Immunodeficiency virus (HIV)1,2 3. Despite having more than 971 000 
people on antiretroviral therapy (ART) in 20094, the programme must grow 
significantly to meet demand for ART 5 6. 
 
The majority of treatment initiation guidelines, including the current WHO 
guidelines 2, are CD4 based. A recent cost-effectiveness analysis 7 
recommended that resource-limited countries with only one line of ART available 
should prioritize access to CD4 count monitoring and ART initiation at CD4 ≤ 350 
cells/µl to offer the best survival outcomes. However, universal access to CD4 
count monitoring is hindered by centralized laboratory services, the challenges of 
transporting samples to these laboratories, cost and delays in receiving results. 
Recent studies in settings that rely on laboratory-based CD4 enumeration have 
shown that only 55-90% of individuals have a CD4 count within 2 to 6 months of 
testing HIV positive, and of those only 46-65% will return to receive their CD4 
count result.8-10. Individuals who are potentially eligible for ART are thus lost to 
care.  
 
The availability of point-of-care (POC) CD4 technology should increase the 
number of CD4 counts done and the number of individuals receiving their results. 
POC CD4 counts may be especially valuable in mobile clinics or when transport 
costs and access to health care facilities (both through user fees and availability 
of staff) are barriers to returning to returning to the facility11,12. For HIV testing 
services, the immediate availability of CD4 count results enables appropriate 
post-test counselling for HIV-infected clients and, when indicated, immediate 
referral for ART. This reduction in treatment delays would improve morbidity and 
mortality 13-15 and decrease transmission of HIV from mother to child16,17.  
The PIMA™ Analyser (PIMA™) (Alere, Waltham, USA) is one of the few 
commercially available POC CD4 machines. Recent evaluations show good 
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correlation between PIMA™ CD4 results and laboratory CD4 counts18-20. To date 
there is a paucity of data from sites such as mobile clinics where the PIMA™ is 
most likely to be used with the greatest benefit. In addition, there are no 
published data comparing the two possible PIMA™ blood collection techniques 
(venous and capillary) on samples taken from the same individual. 
 
We evaluated the PIMA™ by assessing CD4 counts obtained from HIV-infected 
patients attending a mobile clinic and determining factors which may impact on 
the performance of the PIMA™.   
Methods 
 
This cross-sectional study comparing PIMA™ and laboratory CD4 results was 
done in a primary care setting in Cape Town, South Africa, on samples obtained 
from patients who accessed a nurse-run, counsellor supported mobile clinic 
between March and November 2010..A CD4 count (PIMA™ and/or laboratory) 
was done as part of routine care for HIV infected individuals. Clients were 
referred for either ART or HIV care based on their CD4 result and clinical staging 
findings. 
 
Study participants consisted of consecutive HIV positive individuals (newly 
diagnosed, known positive not on ART and known positive on ART) identified in 
the mobile clinic who consented to having both PIMA™ and laboratory CD4 
counts done. A subset of individuals consented to having both capillary and 
venous PIMA™ CD4 counts and a laboratory CD4 count performed. 
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PIMA™ CD4 testing 
 
The PIMA™ CD4 test enables the determination of absolute counts of CD4 T- 
lymphocytes in whole blood without prior sample preparation. Full details are 
described elsewhere18. 
 
The PIMA™ is particularly suitable for mobile clinic settings as it can be readily 
transported to site in the carrier bag provided, can be battery operated and has 
no liquid bio-hazardous waste. In addition it is easy to operate, requires no 
specific technical skills to do so and requires minimal maintenance. The 
cartridges are heat stable and the cost per test (excluding the price of the 
machine) is no more expensive than a laboratory CD4 count.  
 
Nine different PIMA™ machines were used over the course of the study. The 
manufacturer’s instructions were followed for installation, operation, storage of 
test materials and running of daily controls. Three training sessions for operators 
were held: one before the study commenced (March 2010) and two additional 
refresher trainings (July and October 2010). The sessions were conducted by 
trained Alere Healthcare representatives and included instruction on the use of 
the PIMA™ device and the correct sample collection techniques.  
 
The required 25µl of blood was collected into a PIMA™ cartridge from a finger 
prick and/or venous sample. Nurses were asked to use a 1.8mm blade lancet for 
the capillary samples. Venous blood was collected by phlebotomy in a 4ml EDTA 
tube and transferred to a PIMA™ cassette by means of a plastic non-calibrated 
pipette or an EDTA-filled capillary tube. Nurses self-selected the method in which 
the sample would be collected unless the individual had consented to both.   
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Laboratory testing 
 
Venous blood collected in a 4ml EDTA tube was kept at room temperature and 
transported to a reference laboratory (Togatainer Gugulethu, Toga, 
Johannesburg, South Africa), usually the next working day. Specimens were 
analyzed using standardized protocols on a Beckman Coulter EPICS XL-MCL™ 
(XL-MCL) flow cytometer (Beckman-Coulter, Miami, FL). Both internal and 
external (AFREQAS through the NHLS) quality control procedures are in place at 
the laboratory. The laboratory personnel were blinded to the PIMA™ results. 
 
Data analysis 
 
Each PIMA™ sample was classified as being either “venous” or “capillary”, 
although some patients had “both”; in these cases, both a venous and capillary 
specimen were taken from the same individual, collected by the same operator 
and analyzed on the same machine. The time, date, operator and machine 
number were reflected on the PIMA™ result printout.  
 
The variable, training, indicates the number of training sessions attended by the 
operator at the time of performing each PIMA™ test.  
 
The number of days taken for the sample to reach the laboratory (days to lab) 
was calculated. A specimen was classified as delayed if “days to lab” was more 
than one day. We intentionally included all samples in our analysis as delays in 
reaching a laboratory are not an uncommon occurrence in Sub-Saharan Africa21 
but repeated our analysis using only those XL-MCL specimens processed at the 
laboratory within one day. 
 
The XL-MCL CD4 results, the “gold standard” were stratified into three 
groups(CD4 group) for further analysis in keeping with current cut-offs for ART 
initiation: XL-MCL CD4 count ≤200; 201 - 350 cells and >350 cells/µl.   
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Statistical analysis: 
 
Statistical analysis used STATA® Version 11 (StataCorp, College Station, USA). 
Data were explored via simple proportions, medians, means, cross-tabulations 
and chi square tests. A Wilcoxon Signed Rank test was used to calculate 
differences in median results. The sensitivity and specificity for the PIMA™ CD4 
results, as well as Kappa statistics, were calculated using laboratory cut-offs of 
200 and 350 cells/µl. Bland-Altman tests were used to determine the systematic 
bias of the PIMA™ relative to the XL-MCL. 
Linear regression analysis was used to identify factors impacting on the 
performance of the PIMA™ for both venous and capillary samples. All models 
were adjusted for the corresponding laboratory XL-MCL value. We modeled 
individual predictors (delay, operator, machine and training) separately. All 
predictors were then included in a single multivariable model.   
The reference group for “machine” consisted of all those machines on which 
there was a non-significant mean difference (i.e. the CI included 0) between the 
PIMA™ and XL-MCL CD4 values. This was done as statistical power was less if 
all machines were included individually. The composition of the reference group 
varied between venous and capillary samples.  
The reference operator was the nurse who had the least significant mean 
difference between the PIMA™ and the XL-MCL results. The reference operator 
was not the same for venous and capillary samples.   
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Ethics 
 
Informed consent was obtained from all study participants. Data collection and 
analysis was approved by the University of Cape Town Research Ethics 
Committee. This study also adheres to the declaration of Helsinki 2008. 
 
The machines were donated by Alere Healthcare, but Alere had no part in 
design, conduct or analysis of the study. 
 
Results 
 
Overall 349 HIV-infected individuals, seen between March and November 2010, 
had PIMA™ and laboratory CD4 results available. A total of 325 venous PIMA™ 
and 167 capillary PIMA™ samples were analyzed as 138 participants had dual 
venous and capillary PIMA™ specimens taken (Figure 1,Appendix 9), 182 had 
only venous PIMA™ and 24 only capillary PIMA™ samples.  
 
The majority (88%) of the 349 study participants were black South African, 
female (63%) and not yet taking ART (82%). The median age was 33 years (IQR 
27-40) (Table 1). The median laboratory CD4 was 405 cells/µl (IQR 277-600) 
(Table 2) with CD4 <=200, 201-350 and > 350 cells/µl being 11%, 29% and 60% 
respectively.  
 
Overall 270 samples (77%) were processed at the laboratory within one day 
whilst the remaining 79 were processed 2-3 days after the sample was taken 
(delayed). The numbers of samples performed by each user and on each 
machine was not consistent, neither was the number of training sessions 
received by the operators (range 0-3) (Table 1).  
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Venous samples 
 
The median venous PIMA™ CD4 result (n=325) of 393 cells/µl (IQR 264-587) did 
not differ significantly from the corresponding median laboratory CD4 count of 
409 cells/µl (IQR 277-609) (p=0.11) (Table 2). The Spearman rank correlation 
co-efficient was 0.96(p<0.0001). Our regression analysis using the gold standard 
revealed a regression coefficient of 0.999 (95%CI 0.964-1.034) (Table 3) (Figure 
2A; appendix 9). Ninety-one percent of the variation in the PIMA™ result was 
explained by the laboratory result (R-square 0.909). Results were similar when 
excluding delayed specimens (Table 3).  
The mean difference (Bland Altman) between PIMA™ CD4 counts and gold 
standard XL-MCL CD4 counts was -4.5 cells/µl (CI -12.5 to 3.4), and -11.4 cells/ 
µl (CI -20.2 ; -2.6) when excluding delayed specimens (Table 3)(Also see Figure 
2B in appendix 9). 
The sensitivity of the PIMA™ in detecting CD4 counts≤200 cells/µl and CD4 
counts≤350 cells/µl was 89% (95%CI 75-97) (Table 4) and 89% (95%CI 82-94) 
respectively. The specificity was 98% (95%CI 96-99) for CD4 counts> 200 
cells/µl and 90% (CI 85 - 94) for >350 cells/µl. 
 
In total ten samples (3.1%; CI 1.5 – 5.6) were misclassified around the threshold 
of 200 cells/µl; four samples above and six samples below the threshold. Those 
individuals misclassified above the threshold would potentially have been 
excluded from ART therapy and those below the threshold would have been 
given ART prematurely. 
The overall misclassification was higher around the 350 cells/µl threshold at 
10.5% (CI 7.4-14.3) with the misclassification of 14 samples above and 20 
samples below the threshold.  
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Capillary samples 
 
The median capillary PIMA™ CD4 result (n=167) of 429 cells/µl (IQR 296-596) 
differed significantly from the corresponding median laboratory CD4 count of 398 
(IQR 269-572) (p<0.0001) (Table 2). The Spearman rank correlation co-efficient 
was 0.93 (p<0.0001).The R-square is 0.88 (Table 3)(Figure 2B in appendix 9). 
The mean difference was 29.7 cells/µl (95%CI 16.9 to 42.5) when compared to 
the gold standard, and 26.7 (CI 13.5 to 40.4) when delayed samples were 
excluded (Table 3) (Figure 2B, appendix 9). 
 
The sensitivity of the PIMA™ in detecting CD4 counts≤200 cells/µl and ≤350 
cells/µl for capillary samples was 81% (95%CI 54-96) and 85% (95%CI 74-92) 
(Table 4) respectively. The specificity was 99% (95%CI 95-100) for CD4 
counts>200 cells/µl and 93% (95%CI 86-97) for CD4 counts >350 cells/µl. 
 
 In a similar pattern to the venous samples, 3.0% (CI 1.0 – 6.8) of capillary 
samples were misclassified around the threshold of 200 and 10.8% (CI 6.5 – 
16.5) around the threshold of 350. With capillary samples however, there were 
more misclassifications above the thresholds than below thus more individuals 
would potentially have been excluded from ART therapy than would have been 
started on treatment prematurely. 
  
Comparison of venous versus capillary PIMA™ samples  
 
A comparison was done between CD4 count results obtained when both venous 
and capillary PIMA™ samples from the same individual by the same operator 
were run on the same machine (n=138). There was a significant difference 
between the venous median CD4 of 406.5 cells/ µl (IQR 262-593) and the 
capillary median CD4 of 436.5 cells/ µl (IQR 299-618) (p=0.0002) in this group 
with a mean difference of 26.1 cells/ µl . As before, the results were similar when 
excluding all delayed samples.  
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The Kappa statistic using a cut-off of 200 cells/ µl was 0.76 and using a cut-off of 
350 cells/ µl was 0.82 
 
Regression Analysis 
 
All linear regression models included the XL-MCL value.  
In the regression analysis of venous samples, operator, machine and training 
and delay all significantly influenced (p<0.05) the performance of the PIMA™ 
Analyzer (Panel I, Table 5). In the multivariable analysis (Panel II, Table 5), 
machine had the biggest effect estimate and delay remained significant 
(p=0.010). Operator was borderline significant (p=0.086).  
 
In the regression analysis of the capillary PIMA™ samples (Panel III, Table 5) 
only machine and training were significant (p<0.05). Delay was however not 
significant. In the multivariable analysis (Panel IV, Table 5) the machines were no 
longer of significance but training neared significance (p=0.058).  
 
Furthermore neither CD4 strata nor the presence/absence of ART contributed 
significantly to the model. 
 
When doing a more rigorous analysis using only samples reaching the laboratory 
within one day (results not shown), machine remained a significant variable for 
venous samples. For capillary samples, none of the variables of interest were 
significant in this analysis.  
 
 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
15 
 
Discussion 
 
These data suggest that the PIMA™ performed well when used on a mobile 
clinic. The CD4 count estimates were more reliable with venous than capillary 
samples. There was an underestimation of CD4 counts using venous samples 
and an overestimation when using capillary samples which is consistent with 
previous studies,18,19,22 and was also consistent when comparing PIMA-based 
CD4 estimates using both venous and capillary samples from the same 
individual. 
 
Although approximately 10% of CD4 results were misclassified using a threshold 
of 350 cells/µl, this was reduced to 3% when using a threshold of 200 cells/µl for 
both capillary and venous samples. These low misclassification rates would 
enable the mobile clinic staff to accurately and urgently refer individuals eligible 
for ART, as per the current South African guidelines. We could be referring 
individuals for ART prematurely, more so for venous than capillary results, but 
this is less serious than missing individuals who require ART.  
 
Our field evaluation reinforces previous findings from both laboratory 19,20 and 
facility based studies 18 that POC CD4 testing, using the PIMA™ Analyzer, may 
be an acceptable alternative to laboratory based CD4 testing when absolute CD4 
T- lymphocytes counts are required. Although several other innovative means of 
assessing CD4 counts have been published over the past few years, they have 
either not been commercialized, not been rolled out on a large scale or are have 
intricate components or operating requirements making them less suitable for a 
nurse-run mobile clinic such as ours 21,23-28.  The latter can be far from ideal: the 
machines are transported over large distances daily, operated on battery power 
and used in varying environmental temperatures and conditions. Despite this the 
machine performed well. 
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Our sensitivity may have improved if our sample size was larger and included 
more individuals with CD4 counts below 200 cells/µl. Our previous study showed 
that individuals accessing this mobile clinic were healthier than those accessing 
hospitals and clinics29. Our median CD4 counts were higher than these previous 
evaluations 18-20 with the majority (60%) of our XL-MCL CD4 counts being over 
350 cells/µl compared to 40% 20 and 20%18. This may have led to a larger bias 
as typically the reliability of the CD4 estimate decreases as the CD4 count 
increases. However the clinical implications of a variation in CD4 cells at higher 
CD4 counts is less.  
 
The PIMA™ machine used appeared to affect the test performance as machine 
remained significant in the multivariable analysis for ven us samples. Some 
variation was noted amongst the operators, but after adjusting for the machine 
used and amount of training received, this was not statistically significant.  
 
Training was significant in the multivariable model for capillary samples. 
Paradoxically, it appears that the more training received the greater the deviation 
from the laboratory result. Although it is unlikely that additional training results in 
poorer performance, the possibility of user fatigue (where operators using the 
machine for longer periods may be less likely to adhere to protocols) needs to be 
considered. In addition, training could be a proxy for calendar effect and needs to 
be understood better. We could have restricted the analysis to only the 2 
operators who had undergone all three training sessions but this would have 
significantly reduced the power of the study. 
 
Our study is subject to several limitations. Firstly our study is a field evaluation 
and the rigor normally associated with a research setting in terms of methodology 
is lacking. The exact time delays between sample collection, sample processing 
on the PIMA™ and sample processing at the laboratory were not calculated. The 
room temperature was also not recorded. The number of specimens performed 
on each machine and each user was not consistent. In addition the number of 
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training sessions attended by each user varied. This was however adjusted for in 
our multivariable analysis. The effects may also have been more apparent if the 
sample size was bigger for capillary samples and samples where the XL-MCL 
result was less than 200. 
 
Secondly the study was run from March to November which are typically the 
cooler months in Cape Town. The impact of ambient temperature on machine 
performance has not been sufficiently evaluated.  
 
Thirdly, poorly collected specimens can adversely affect the quality of CD4 
enumeration. The collection of venous blood into an EDTA tube using a BD 
Vacutainer® system (Becton, Dickinson and Company, Franklin Lakes, NJ) and 
transfer of the sample with a pipette could have caused shearing, deterioration or 
loss of cells. Furthermore the blood-to-additive ratio may be altered through the 
additional use of EDTA-filled capillary tubes contributing to the slight 
underestimation of CD4 counts seen for venous samples.  
Collection of the capillary samples also requires a well-trained individual. Despite 
the nurses being highly experienced and trained in finger-prick blood collection, 
the collection of blood into the PIMA™ cartridge was challenging initially. 
Insufficient volume or the presence of air bubbles in the sample adversely affects 
the accuracy of the PIMA™ result. If the PIMA™ is to be used by inexperienced 
or careless operators, the overall performance of the PIMA™ may not be as 
good as reported in our study or previous studies.  
  
Fourthly, our nurses were not blinded to the PIMA™ results which may have 
been important when performing dual samples. This may have resulted in repeat 
specimens being performed. 
 
Lastly, we had an imperfect gold standard. A universally accepted gold standard 
for CD4 counts does not exist but flow cytometers such as the FACScount and 
Beckman Coulter CD4 counts are often used. The gold standard in this study is 
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further influenced by a delay in reaching the laboratory which was found to be 
significant in our study. Delays in our study typically occurred because the 
reference laboratory does not provide an after-hours or weekend service. Both 
other evaluations 18 19 used same day laboratory specimen processing. Whilst 
this gives a more accurate comparison, this does not take into account the fact 
that blood samples from most testing sites where POC would be most useful, 
could take days to reach the laboratory. Clinicians wanting to perform their own 
validations, especially at rural sites, should bear this in mind.  
 
For accurate results, specimens must be analysed no later than 48 hours after 
collection as delays result in sample aging. This could induce apoptosis of cells 
resulting in an underestimation of CD4 counts. However aging can cause 
changed cell morphology altering light scatter properties. Distinguishing between 
monocytes & lymphocytes thus becomes difficult. Automated gating algorithms 
may fail to identify the relevant populations and manual gating may need to be 
performed. If monocytes are counted as T-helper cells it could lead to an 
increased CD4 count (W.Pretorius [willem.pretorius@alere.com],email,May 16, 
2011).The latter could be a reason for finding that delay had a positive effect size 
for both venous and capillary samples in our study.  
The potential advantages of giving CD4 results to the individual during the 
timeframe of their initial consultation are considerable. We were able to give 99% 
(n=346) of patients their PIMA™ result during their visit. This is a significant 
improvement over the 46-65% of individuals who return to their health care 
facility to receive their CD4 count result.8-10. 
Future research may examine whether the use of POC CD4 results in improved 
referrals to care. An evaluation of the linkage-to-care of these individuals is 
warranted to assess the cost-effectiveness of POC CD4 counts.  
 
Pregnant patients and those with TB, where a cutoff of 350 applies, may need 
confirmatory CD4 count testing at their referral site due to the 10% 
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misclassification at this level. Further validation studies of the PIMA in these two 
populations may need to be done. 
 
The significant variability between machines needs to be further explored. 
 
Conclusion 
 
Our field evaluation reinforces previous findings that the PIMA™ Analyzer may 
be an acceptable alternative to laboratory based CD4 testing for absolute CD4 T- 
lymphocytes counts. Misclassification rates are low when using a CD4 cutoff of < 
200 cells/ µl enabling accurate identification of individuals requiring ART. In our 
evaluation venous samples underestimated and capillary samples overestimated 
the XL-MCL CD4 result. Operator, machine and training appeared to influence 
the performance of the PIMA™ and this finding needs to be further evaluated.  
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Table 1. Basic demographic data 
Variables 
Total 
Venous 
PIMA 
Capillary 
PIMA 
Both  
N=349 N=325 N=167 N=138 
median IQR mean sd mean sd mean sd 
  (range)             
age   33 
27-40 
(16-72) 
- - - - - - 
    N % N % N % N % 
HIV 
newly 
diagnosed 
183 52.4 173 53.2 76 45.5 64 46.4 
known not on 
ART 
102 29.2 91 28.0 50 29.9 37 26.8 
known on ART 64 18.3 61 18.8 41 24.6 37 26.8 
gender 
male 129 37.0 124 38.1 51 30.5 44 31.9 
female 220 63.0 201 61.9 116 69.5 94 68.2 
LAB CD4 (cell/µl)  
<=200 38 10.9 38 11.7 16 9.6 15 10.9 
201-350 103 29.5 91 28.0 55 32.9 41 29.7 
> 350 208 59.6 196 60.3 96 57.5 82 59.4 
days to lab 
0 8 2.3 8 2.5 8 4.8 8 5.8 
1 262 75.1 239 73.5 127 76.1 101 73.2 
2 51 14.6 50 15.4 19 11.4 16 11.6 
3 28 8.0 28 8.6 13 7.8 13 9.4 
delay 
yes 79 22.6 78 24.0 32 19.2 29 21.01 
no 270 77.4 247 76.0 135 80.8 109 78.99 
operator 
operator A     69 21.2 40 24.0 33 23.9 
operator B     37 11.4 3 1.8 3 2.2 
operator C     69 21.2 52 31.1 51 37.0 
operator D     150 46.2 72 43.1 51 37.0 
machine 
A 
 
  72 22.2 60 35.9 47 34.1 
B 
 
  24 7.4 23 13.8 22 15.9 
C     4 1.2 6 3.6 4 2.9 
D     19 5.8 5 3.0 4 2.9 
E 
 
  127 39.1 49 29.3 40 29.0 
F 
 
  50 15.4 10 6.0 8 5.8 
G 
 
  13 4.0 1 0.6 1 0.7 
H 
 
  15 4.6 13 7.8 12 8.7 
I 
 
  1 0.3 0 0.0 0 0.0 
Number of training 
sessions  
1     189 58.2 41 24.6     
2     95 29.2 87 52.1     
3     41 12.6 39 23.4     
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Appendix 1: Client form (version 26 Jan 2010) 
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Data ________ (for office use only) 
 
DATE:  _____________    Client initials: __  __   __ 
   DD-MMM-YYYY 
DATE OF BIRTH: ______________ GENDER:  □  Male   □  Female  
           DD-MMM-YYYY 
RACE:  □ Black SA  □ Coloured □ Asian □ White □ Other_________________ 
 □ Black non SA 
 
Tested before on our mobile clinic? □ No □ Yes (add details) date: __________where______________ 
 
Weight: ____________ Height: _____________ BMI = ___________ 
 
Waist circumference: __________ 
 
Pretest counselling session needed? □ Yes □ No                Couple counselling □ Yes □ No   
 
NURSE: __________________ 
 
 
HAVE YOU EVER HAD A HIV TEST? 
□ No / never 
□ < 3 months ago   
□ 3-6 months ago 
□ 6-12 months ago 
□ More than a year ago - Which year?_________ 
 
Most recent HIV Result: □ NEG □ POS         Are you on ART?     □ yes □ no □ defaulted 
When was your last CD4? ______________(month / year) 
 What was your last CD4? ____________ 
 
MEDICAL HISTORY: 
Have you ever had your Blood pressure checked:      □ No  □ yes  □unsure    
If yes, Were you put on treatment? □ No  □ yes      Are you still on treatment?  □ No  □ yes 
 
Have you ever had our glucose (diabetes) checked:  □ No  □ yes   □unsure      
If yes, Were you put on treatment? □ No  □ yes       Are you still on treatment? □ No  □ yes 
 
Have you ever had a sexually transmitted Infection before? □ No  □ yes  □ unsure 
Insert sticker  or add …. 
 
Site: __________ 
 
Number:________ 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
       
Version JAN 2010 
Ever had a Pap smear? 
□ Not applicable (male)  
□ Yes         □ < 5 years ago □  5-10 years ago  □ >  10 years ago(refer)       
Results: □ Normal  □  Abnormal  □ Didn’t get results 
□ No (refer if > 30 years old)       
□ too young (< 30)    
 
Have you ever had Tuberculosis? □ No  □ yes    
      If yes, Are you currently on treatment? □ No  □ yes    
If yes, did you complete TB treatment? □ No  □ yes    
(if treatment not completed discuss and refer if necessary – especially if a recent defaulter) 
 
Obtained verbal consent for HIV test?  □ Yes  □ No  
 
Couple testing: □ Yes □ no  
 
Bioline HIV result  Abbott Determine HIV result  
□ Positive      □ Not applicable 
□ Negative    □ Known pos 
□ Known pos    □ Positive 
□ Not done    □ Negative 
□ Not applicable    □ Not done 
 
 
Overall HIV Result:  □ Negative      □ Indeterminate    
□ Newly diagnosed HIV Positive *****  □ Refused test   
□ Known HIV Positive – on ART***   □ Not tested other reason    
□ Know  HIV Positive – not on ART *   __________________
  
 
Blood pressure: _ _ _ / _ _ _ If > = 140 / 90  □ new diagnosis  □ on treatment  □ defaulted treatment 
 
DIABETES RISK SCORE: 
 
Glucose: _ _ . _   If > 7.0: (please circle)  Random  Fasting  
If > 11.0 or > 7 (fasting) - □ new diagnosis  □ on treatment  □ defaulted treatment  
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Client Number:___________ 
TB symptoms?    □ No  □ Yes (refer) 
  
STI symptoms?   □ no  □ yes (refer)  
 
Needs a pap smear?  □ Not applicable /male      □ Yes(refer) □ No   □ too young (< 30)    
         
CNP: ______________________ 
If HIV Positive: 
 
Blood taken for a CD4 count?   □ yes*  □ POINT OF CARE CD4 _________________ 
      □ LAB CD4 
       □ no  ___________________________________ 
□ n/a – on HAART (and regularly monitored) 
□ n/a – last CD4 was > 350 (done less than 6 months ago) 
□ n/a – last CD4 was >200 and <350 (done less than 3 months ago) 
□ refused 
* take blood for CD4 if they are part of the TB study  
 
Syphilis screen: □ negative   □ positive   □ not done   □ n/a  
 
Pregnancy test: □ negative  □ positive □ not applicable      □ not done 
 
Clinical Stage:    □ 1  □ 2  □ 3   □ 4 □ on ART □ not done 
 
Overall assessment:  □ on ART  □ Green  □ Yellow □ Red    Referred for ARVs?  □ no   □ yes   
 
Active STI screen:   □ no □ yes  □ not done 
 
 
For patients with STIs: 
Syphilis screen:  □ negative   □ positive  □ not done    □ not applicable   
             
        Sample sent to lab for RPR? □ Yes  □ No  
STI treatment:  □ no □ yes  - code __________  
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CONDOM DEMONSTRATION (Must be done!. If not done by nurse MUST be done by counsellor) 
Did patient demonstrate how they use condoms?  □ no □ yes  (initials of person observing:)________ 
If no, document why not:_______________________________________________ 
 
COUNSELLOR: __________________                           
Have you had a sexual partner in the past 3 months? 
 
□ yes  
□ not yet sexually active  
□ not sexually active for > 1 year  
□ last partner 3 – 6 months ago  
□ last partner 6 – 12 months ago 
 
Sexual orientation 
□ Straight (heterosexual) 
□ Homosexual / lesbian 
□ Bisexual 
 
 
If HIV NEGATIVE:   HIV Result given to patient?  □ yes  □ no 
Total Risk factors (0-10): ______ □ not done 
     Overall Risk assessment:  □ low  □@ risk   □ high  
    Next test date: □ 3 months □ 12 months □ before sexually active (again) 
     
If HIV POSITIVE:  HIV Result given to patient?  □ yes  □ no 
Post test counselling done:  □ yes   □ no  □ n/a 
Risk reduction done:   □ yes   □ no  
“Road to HIV health” card given and explained?  □ yes  □ no 
Any other information ……………………………………………………………………………………………… 
 
TB testing: SPUTUM sent to the lab today? □ yes  □ no   □ unable  □ refused 
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Client  Number:______________ 
 
RISK FACTORS:   
low 
risk @ risk Total 
1. Have all your current sexual partners tested for HIV?  
(unknown partner status) n/a yes 
No / 
don’t know 
(1 point)  
2. Are any of your sexual partners HIV positive?  
(discordancy) n/a no 
Yes/ 
Don’t know 
(1 point)  
3. Did you use condoms every time you had sex in the past 3 
months?  
(unprotected sex) n/a Yes 
No  
(1 point)  
4. Have you had more than one sexual partner in the past 3 
months or is your partner having other partners? 
(multiple partners) n/a No 
Yes 
(1 point)  
5. is your partner more than 10 years older/ younger than you 
(intergenerational sex)  n/a no  
Yes 
(1 point)  
6. Did you have anal sex with someone in the past 6 months? 
 n/a no 
Yes 
(1 point)  
7. Did you have sex with someone for food, airtime, clothes, 
money, etc. in the past 6 months? 
(transactional sex) n/a no 
Yes 
(1 point)  
8. Have you or your partner had a STI in the past 6 months? n/a no 
Yes  
(1 point)  
9. Have you injected drugs/ had a tattoo/ needed blood products in 
the past 6 months? n/a no 
Yes 
(2 points)  
   
TOTAL 
  
 
0 = low risk = test yearly unless in window period 
1 = @ risk = test in 3 months – 12 months (depending on risk factor and if in window period)  
2 or more = high risk= test in 3 months time 
Is there a risk factor which can be addressed?  ⁪ No ⁪ Yes 
 
Behaviour Costs Benefits 
  
 
 
 
 
 
My specific goal is to: _____________________________________________________ 
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Appendix 2: Ethical approval: Active Tuberculosis Case Finding  
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UNIVERSITY OF CAPE TO\\1N 
• 
4 February 2009 
REC REF: 507/2008 
DrKKranzer 
Desmond Tutu 
HIV Foundation 
IIDl\1J\1 
Medical School 
Dear Dr Kranzer 
Health Sciences F acuIty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021]4066338 • Facsimile [021] 4066411 
e-mail: shuretta.thomas@uct.ac.za 
PROJECT TITLE: ACTIVE TUBERCULOSIS CASE FINDING IN INDffiDUALS ACCESSING 
A MOBILE VOLUNTARY COUNSELLING AND TESTING SERVICE. 
Thank you for submitting your study to the Research Ethics Committee for review. 
It is a pleasure to inform you that the Ethics Committee has formally approved the above-mentioned study. 
Approval is granted for one year till the 8th February 2010. 
Please submit an annual progress report if the research continues beyond the expiry date. Please submit a brief 
summary of findings if you complete the study within the approval period so that we can close our file. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the REC. REF in all your correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN 
CHAIRPERSON. HSF HUMAN ETHICS 
Federal Wide Assurance Number: FWA00001637. 
Institutional Review Board (IRB) munber: IRB00001938 
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• 
This serves to confinn that the University of Cape Town Research Ethics Committee complies to the Ethics 
Standards for Clinical Research with a new drug in patients, based on the Medical Research Council (MRC-
SA), Food and Drug Administtation (FDA-USA), International Convention on Harmonisation Good Clinical 
Practice (ICH GCP) and Declaration of Helsinki guidelines. 
The Research Ethics Committee granting this approval is in compliance with the ICH Harmonised Tripartite 
Guidelines E6: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) and FDA Code Federal 
Regulation Part 50, 56 and 312. 
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Appendix 3: Ethical approval Cross-sectional survey 
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UNIVERSny OF CAPE TOWN 
13 September 2010 
HREC REF: 262/2010 
DrKKraDZer 
Desmond Tutu HIV Foundation 
IIDMM Medical School 
Dear Dr Kmnzer 
Health Sciences Faculty 
Faculty of Health Sciences Rescarch Ethics Committee 
Room ES2-24 Groote Schuur Hospital Old Main Building 
Ohsetvatoty 7925 
Telephone [021] 4D6 6338 • Facsimile l021] 4D6 6411 
e-mail: stunayah.acictilien@uct.ac.za 
PROJECT TITLE: CROSS·SECTIONAL SURVEY OF HIV INFECfION AND CD4 COUNTS 
IN MASIPHUMELELE TOWNSHIP 
'111ank you for your letter to the Faculty of Health Sciences Research Ethics Committee dated 31" August 
2010. 
It is a pleasure to inform you that the Ethics Committee has approved the following documelltation with 
reference to the above mentioned study:-
• CD-4 Survey Sub-study 1, V ctsion 1.0 
• CD·4 survey Sub-study 2, Version 1.0 
• Adult info.ttned consent form. Cross-sectional su!;\'9 version 3.0 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the REC, REF in all you~ correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN 
CHAIRPERSON, HSF HUMAN ETHICS 
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Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
5 
 
Appendix 4: Data collection form for PIMA™ results 
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  CD4 survey 
  Sub Study 
  Version 1.0 
   
Page 1 of 1 
 
 
 
TUTU tester PIMA study: capillary versus venous blood 
Tutu Tester number 
  
Date of test 
  
     
Capillary blood 
 
 
 
If no print out available, please fill in by 
hand: 
 
CD4 result                   ___________ 
  
PIMA machine            ___________ 
 
Operator                     ___________ 
 Venous blood 
 
 
 
If no print out available, please fill in by 
hand: 
 
CD4 result                   ___________ 
  
PIMA machine            ___________ 
 
Operator                     ___________ 
 
Toga lab result 
  
 
 
Entered by: ___________________  Date: _____________________ 
 
Entered by: ___________________  Date:______________________ 
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Appendix 5: Client details sheet 
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PASSION | INNOVATION | PROGRESS 
 
Association Incorporated under Section 21: Registration No: 1999/005072/08 
Public Benefit No: 18/11/12/51 
Directors: Prof R Wood; Prof L-G Bekker; Prof G Kaplan; 
Prof D Martin; Ms Z Ebrahim; Mr P-D Uys; Mr T Papier; Ms T Tutu-Gxashe 
 www.desmondtutuhivfoundation.org.za 
Level 1 
Wernher Beit North Building 
Faculty of Health Sciences  
Anzio Road, Observatory, 
Cape Town, South Africa 
 
P O BOX 13801, MOWBRAY, 7705 
Cape Town, South Africa 
(T) 27 021 6506966   
(F) 27 021 6506963 
VAT No. 4750185565 
DESMOND TUTU HIV FOUNDATION 
 
Client number #:____________________________  Date of birth: ___________________________  
 
Participant Name:  ___________________________       Other Names:  __________________________ 
 
Personal Cell No:  __________________________   May we sms you? Yes / No  
       Language:    English   /   Afrikaans   /    Xhosa 
       Messages:    Bland     /   HIV-specific 
 
OK to leave a voicemail message? Yes / No  
                                                                                 If so, who shall we say is calling?_________________ 
 
OK to leave a message if someone else answers your phone? Yes / No  
       If so, who shall we say is calling?_________________ 
____________________________________________________________________________________________ 
 
Home Tel:  ____________________________    OK to leave Message Y/N: _____ 
       If so, who shall we say is calling?_________________ 
____________________________________________________________________________________________ 
 
Work No:  _____________________________    OK to leave Message Y/N: _____ 
       If so, who shall we say is calling?_________________ 
____________________________________________________________________________________________ 
 
Home address:_____________________________  Postal address (if different): _______________           
__________________________________________  _______________________________________ 
__________________________________________  _______________________________________ 
 
May we come to your home? Y/N ___________ 
 
If yes,  with whom do you live? ______________________________ 
Formal or Informal Dwelling:  __________________________ 
Nearest landmark (e.g. next to church):  ___________________ 
 
Clinic you are most likely to use:_________________   Nearest Hospital:  _______________________ 
Clinic folder # (if known): _______________________  Hospital folder # (if known): ______________ 
 
Client Signature: _______________________  Date:____________________________________ 
 
Staff Signature:_________________________              Date:_____________________________________ 
 
Protection of Confidentiality 
Note:  When we leave phone messages, we will never reveal information without your prior approval. 
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Appendix 6: Ethical approval for reporting of programmatic data from Tutu 
Tester 
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__ UNIVERSI~ CAPE TOWN 
03 June 2010 
Prof LG Bekker 
Desmond Tutu HIV Centre 
IIDMM 
Medical School 
Dear Prof Bekker 
Health Sciences Faculty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 4066338 • Facsimile [021] 406 6411 
e-mail: lamees.emjedi@uct.ac.za 
----------------
RE: PERMISSION TO REPORT PROGRAMMATIC DATA 
Thank you for your letter to the Health Science Faculty Human Research Ethics Committee dated 28 May 
2010. 
1. Permission is granted to publish the data anonymously collected in the Tutu Tester. 
2. Do the researchers feel it is worthwhile establishing a data registry with a formal HREC REF number 
for these data? The protocol application would include the information already described in this letter 
and would need an application form. 
Please note that the ongoing ethical conduct of the study remams the responsibility of the principal 
investigator. 
Please quote the REC. REF in all your correspondence. 
Yours sincerely 
.~_t1J2~ _ _ 
PROFESSOR M BLOCKMAN ef CHAIRPERSON. HSF HUMAN ETHICS 
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Appendix 7: Cross-sectional Survey Consent form 
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  Cross-sectional Survey 
  Version 3.0 
Adult informed consent form 
 
Version 3  1
 
       Plot number   ________ 
       HH number  ________ 
       Sex   ________ 
       Age   ________ 
 
Cross-Sectional Survey of HIV infection and CD4 counts in the Masiphumelele Township 
 
INTRODUCTION 
 
You are being invited to take part in this research study because you are a resident of 
Masiphumelele. The doctor in charge of this study at Masiphumelele is: Dr. K Kranzer. Before you 
decide if you want to be a part of this study, we want you to know about the study.  
 
This is a consent form. It gives you information about this study. The research staff will talk with you 
about this information. You are free to ask questions about this study and discuss any worries you 
may have with the research staff. If you agree to take part in this study, you will be asked to sign this 
consent form. You will be given a copy of the form to keep. 
 
WHY IS THIS STUDY BEING DONE? 
 
We want to know how many people are infected with HIV in Masiphumelele and we want to know how 
many people need antiretroviral treatment (treatment of HIV).  
This is a non-interventional study. This means that you will not be provided with treatment on this 
study.  
 
We also want to know if we get better (more accurate) D4 counts if we take blood from your finger 
than if we take blood from your arm to do a CD4 count on the PIMA Analyzer. This is a machine 
which can do your CD4 count immediately rather than sending it to the laboratory. 
 
In the future we may want to do a “viral load” (counting how much virus there is) on the blood of those 
testing positive. We will ask if we can freeze your blood sample in the mean time. 
 
WHO CAN TAKE PART IN THE STUDY? 
 
We have randomly chosen 1300 people living in Masiphumelele. “Random” means that these people 
were chosen out of a hat. This means we do not know anything about them, if they have HIV or if they 
take antiretroviral therapy or not. All randomly chosen people 15 years and older, who have lived in 
Masiphumelele for longer than one week, can be screened to take part in the study. The whole study 
will take about four months to complete. 
 
Anyone testing HIV positive can give permission for more than one CD4 count to be done and can 
give permission to have their blood stored. 
 
WHAT DO I HAVE TO DO IF I TAKE PART? 
 
You have been visited at your home. At this visit a study staff member explained the study to you and 
answered any questions you may have had about the study. If you are interested in taking part, the 
field worker will invite you to attend the TUTU tester, a mobile HIV testing service, any time it is 
parked on Xhosa square.  
 
When you arrive at the TUTU tester you will be offered a choice: 
 
1. You can register as a client of the TUTU tester and undergo HIV testing and counselling and 
screening for other chronic diseases. You will be informed about your HIV-test result and you 
will be given post-test counselling. 
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  Cross-sectional Survey 
  Version 3.0 
Adult informed consent form 
 
Version 3  2
 
If you test HIV-positive, we will take blood from your arm (venous sample) for a CD4 count.  
As part of a sub-study we would like to ask if we can do an additional finger prick and do a 
CD4 count using this blood. We would also like to take an extra tube of blood to do a CD4 
count at the TOGA laboratory. You will get this result if you give us your telephone number or 
you can come back to the TUTU TESTER and we will give it to you. 
 
2. You can to register as a client of the TUTU tester and undergo screening for chronic diseases 
and to provide a venous blood sample. An HIV test will be done on the blood, but your name 
will not be written on the specimen. In this way, we will be able to see how many people have 
HIV, but we will not know your individual HIV status. We will not know if YOU are HIV positive 
or negative. A CD4 count test will be done on your blood sample if it is HIV positive. You will 
not know your HIV-test result. 
 
3. You can to provide a venous blood sample. An HIV test will be done on the blood, but your 
name will not be written on the specimen. In this way, we will be able to see how many people 
have HIV, but we will not know your individual HIV status. We will not know if YOU are HIV 
positive or negative. A CD4 count test will be done on your blood sample if it is HIV positive. 
You will not know your HIV-test result. 
 
We will also ask you some questions about your age and if you are taking antiretroviral therapy.  
 
We would also like to obtain your consent to store your blood sample once we have done a CD4 
count on it. Your blood sample will be labelled only with your study number and stored in a freezer 
specially designed for storing blood samples. We would like to do a “viral load” test on your blood in 
the future. This test will determine how much virus there is in your blood. You will not receive these 
results. 
 
WHAT ARE THE RISKS OF TAKING PART IN THE STUDY? 
 
There are no significant risks to participating in this study.  
 
WHAT ARE THE BENEFITS OF TAKING PART IN THE STUDY? 
 
If you undergo HIV testing and counselling and you are found to have HIV we will refer you to 
Masiphumelele clinic where treatment is available free of charge. If you chose not to be registered as 
Tutu tester client we will not give you your HIV-test result and there will be no further action. 
 
 
WHAT ABOUT CONFIDENTIALITY? 
 
The study team will keep your personal information confidential. You will be given a study number. 
The questionnaire and blood specimens will be labelled with this study number and NOT with your 
name. All information will be kept in a locked cupboard. We will make every attempt to ensure 
confidentiality. Any publication of this study will not use your name or identify you personally. 
 
If your blood is sent to the laboratory and you have asked us to give you your results, your contact 
information will be kept in a locked cupboard. This information is only available to study staff.  
 
 
WHAT ARE THE COSTS TO ME? 
 
There are no costs to you if you are involved in this study.  
 
 
WILL I RECEIVE ANY PAYMENT? 
 
You will not be paid for taking part in this study. However you will receive a 70R gift voucher to 
compensate your time.  
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  Cross-sectional Survey 
  Version 3.0 
Adult informed consent form 
 
Version 3  3
 
 
WHAT ARE MY RIGHTS AS A RESEARCH SUBJECT? 
 
Taking part in this study is completely voluntary. You may choose not to take part in this study. You 
will not be giving up any of your legal rights by signing this consent form.  
 
INVOLUNTARY WITHDRAWAL OR EARLY WITHDRAWAL 
 
If at any time during the study you refuse to complete one of the study procedures or the study team 
deems it unsafe to proceed, you will be withdrawn from the study. You may also decide at any point 
that you no longer wish to participate in the study and may then withdraw from the study by informing 
the study staff about your decision. 
 
In either event, you will be free to withdraw from the study with no further obligations. 
 
CAN I REFUSE TO TAKE PART IN THE STUDY? 
 
Yes, you may refuse to take part in the study. If you decide not to take part in the study, this will not 
affect any medical care or treatment you may require now or in the future. 
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
 
If you have any questions about this study or a research related injury, you may contact: 
 
 Dr Katharina Kranzer at (021) 633 6599  
 
This study has been approved by the the Human Research Ethics Committee of the University of 
Cape Town and the Ethics Committee of the London School of Hygiene and Tropical Medicine. 
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  Cross-sectional Survey 
  Version 3.0 
Adult informed consent form 
 
Version 3  4
 
SIGNATURE PAGE 
 
If you have read this consent form (or have had it explained to you), all your questions have been 
answered, and you agree to take part in this study, please indicate which study you agree to take part 
in and sign your name below. If you are unable to sign, you can make a thumb print in the designated 
space. 
 
 
I agree to take part in the CD4 count survey □ yes   □ no 
 
 
□  I will test as a TUTU tester client and receive my HIV result  
□  I will test as a TUTU tester client but do not want to receive my HIV result 
□  I will give venous blood but do not want to receive my HIV result 
 
I agree to have my blood stored for viral load testing in the future if I test HIV positive 
   □ yes  □ no 
 
For TUTU tester clients receiving HIV test results only: 
I agree to give an extra venous sample and a fingerpick sample for CD4 count testing if I test HIV 
positive 
   □ yes  □ no  
 
 
 
 
 
 
 
____________________________      _______________________     ___________ 
 Participant’s Name (Print)    Participant’s Signature      Date 
 
 
 
 
 
____________________________      _______________________     ___________ 
 Study Staff Conducting        Study Staff’s Signature      Date 
 Consent Discussion (Print)     
 
 
 
 
 
 
____________________________      _______________________     ___________ 
Witness’ Name (Print)    Witness’ Signature        Date 
     (As appropriate) 
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JAIDS: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Instructions for Authors
SCOPE
JAIDS: Journal of Acquired
Immune Deficiency Syndromes is a peer-
reviewed, multidisciplinary journal direc-
ted to an audience of physicians and
researchers. The journal publishes original
work in the form of Original Articles,
Implementation and Operational Re-
search*, Rapid Communications, Critical
Reviews, Brief Reports, and Letters to the
Editor*. JAIDS does not publish case
reports. (*published online only)
MANUSCRIPT SUBMISSION
A submitted manuscript must be an
original contribution not previously pub-
lished (except as an abstract or preliminary
report), must not be under consideration for
publication elsewhere, and, if accepted,
must not be published elsewhere in similar
form, in any language, without the consent
of Lippincott Williams & Wilkins. Each
person listed as an author is expected to
have participated in the study to a signifi-
cant extent. Although the editors and
referees make every effort to ensure the
validity of published manuscripts, the final
responsibility rests with the authors, not
with the journal, its editors, or the publisher.
All submissions will be rigorously
peer-reviewed by members of the Editorial
Board and by other specially qualified
individuals as well. In the interests of rapid
reviewing of contributions, only one of the
Editors-in-Chief will, in general, make the
final determination as to the acceptability of
a submission, after collecting the referee’s
comments. Contributors are required to
recommend specific names of reviewers
from the Editorial Board, as well as other
individuals they deem especially well quali-
fied. However, the Editors-in-Chief will not
be bound to follow such suggestions.
In general, the instructions for
preparation of manuscripts should follow
the International Committee of Medical
Journal Editors (ICMJE) Uniform Require-
ments for Manuscripts Submitted to Bio-
medical Journals. In case of questions,
please feel free to contact the Editorial
Office of any one of the Editors-in-Chief.
Authors must submit their manu-
scripts to the relevant section through
the Web-based tracking system: Basic
and Translational Science (http://jaids-
basicscience.edmgr.com), Clinical Science
(http://jaids-clinical.edmgr.com), or Epi-
demiology and Prevention (http://jaids-
epidemiology.edmgr.com). The site con-
tains instructions and advice on how to use
the system, guidance on the creation/
scanning and saving of electronic art, and
supporting documentation. In addition to
allowing authors to submit manuscripts
on the Web, the site allows authors to
follow the progression of their manuscript
through the peer review process. Authors
should not send hard copies of the manu-
script or artwork to the editorial office.
Address all inquiries regarding manuscripts
not yet accepted or published to the
Journal’s editorial office. The editorial
office will acknowledge receipt of your
manuscript via e-mail.
Editorial Office Addresses
Basic and Translational Science
David D. Ho, MD
The Aaron Diamond AIDS
Research Center
455 First Avenue
New York, NY 10016
917-797-6056
dgottwal@adarc.org
Clinical Science
Paul A. Volberding, MD
San Francisco VA Medical Center
4150 Clement Street
VAMC 111
San Francisco, CA 94121
(415) 379-5546
Fax: (415) 750-2182
jaids@chi.ucsf.edu
Epidemiology and Prevention
William A. Blattner, MD
Institute of Human Virology
725 W. Lombard Street, S419
Baltimore, MD 21201
(410) 706-1292
Fax: (410) 706-1731
cedelen@ihv.umaryland.edu
Authorship
An author is considered to be
someone who has made substantive con-
tributions to a published study. Each author
should have participated sufficiently in the
work to take public responsibility for
appropriate portions of the content. More
specifically, authorship credit requires a)
substantial contributions to conception and
design, or acquisition of data, or analysis
and interpretation of data; b) drafting the
paper or revising it critically for important
intellectual content; and c) final approval of
the version to be published. Contributors
must meet conditions for a, b, and c—all
3—to be eligible for authorship. All persons
listed as authors must meet the 3 criteria
above, and all persons who meet the above
criteria must be listed as authors. Please note
that acquisition of funding, collection of
data, or general supervision of a research
group, alone, does not justify authorship.
For large, multicenter group
studies, individuals who accept direct
responsibility for the manuscript must be
identified. Those individuals will be re-
quired to complete the JAIDS Copyright
Transfer Agreement.
Contributors who do not meet the
criteria for authorship should be listed in
the acknowledgments section. Persons
providing technical help, writing assis-
tance, or a department chair providing
general support are examples of persons
who should not be included as authors, but
who should be listed in the Acknowledg-
ments section.
Conflict of Interest Declaration
Authors must disclose all financial
and personal relationships that might bias
their work. Conflicts of interest must be
detailed in the online submission process as
well as on the title page of the manuscript.
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Conflicts that are determined to be
substantial may be printed in the journal
in a footnote on the first page of the article.
Studies funded by an agency with a
proprietary or financial interest in the
outcome must include a statement with
information about the sponsor(s) involve-
ment. Authors involved in such a study
must state whether they had full access to
all of the data and take full responsibility
for the accuracy of the data analysis.
Copyright
All authors must complete and sign a
copy of the journal’s Copyright Transfer
Agreement and submit it when submitting
the original manuscript online.
Compliance with NIH and Other
Research Funding Agency
Accessibility Requirements
A number of research funding
agencies now require or request authors
to submit the post-print (the article after
peer review and acceptance but not the final
published article) to a repository that is
accessible online by all without charge. As
a service to our authors, LWWwill identify
to the National Library of Medicine (NLM)
articles that require deposit and will trans-
mit the post-print of an article based on
research funded in whole or in part by the
National Institutes of Health, Wellcome
Trust, Howard Hughes Medical Institute, or
other funding agencies to PubMed Central.
The Copyright Transfer Agreement pro-
vides the mechanism.
Patient Anonymity and Informed
Consent
It is the author’s responsibility to
ensure that a patient’s anonymity be care-
fully protected and to verify that any experi-
mental investigation with human subjects
reported in the manuscript was performed
with informed consent and following all
the guidelines for experimental investiga-
tion with human subjects required by the
institution(s) with which all the authors are
affiliated. Authors should mask patients’
eyes and remove patients’ names from
figures unless they obtain written consent
from the patients and submit written
consent with the manuscript.
Protection of Human Subjects and
Animals in Research
When reporting experiments involv-
ing human subjects, authors should in-
dicate whether the procedures followed
were in accordance with the ethical stand-
ards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration
of 1975, as revised in 2000.
For research involving animals,
authors should indicate whether the pro-
cedures followed were in accordance
with the standards set forth in the Guide
for the Care and Use of Laboratory
Animals (published by the National
Academy of Science, National Academy
Press, Washington, D.C.).
Permissions
Authors must submit written per-
mission from the copyright owner (usually
the publisher) to use direct quotations,
tables, or illustrations that have appeared in
copyrighted form elsewhere, along with
complete details about the source. Any
permissions fees that might be required by
the copyright owner are the responsibility
of the authors requesting use of the
borrowed material, not the responsibility
of Lippincott Williams & Wilkins.
PREPARATION OF
MANUSCRIPT
Manuscripts that do not adhere to the
following instructions will be returned to
the corresponding author for technical
revision before undergoing peer review.
ARTICLE LIMITATIONS –
BEGINNING WITH JULY 15, 2010
SUBMISSIONS:
Online Submission
Manuscript files must be uploaded
into the Editorial Manager online interface.
Most word-processing file formats are
acceptable. Editorial Manager will then
create PDF files of the authors’submission,
and the author must view and approve the
files before they will be submitted to
the editorial office. Please be sure that
the manuscript file contains complete text
for your submission (title page and ab-
stract), as this is the file that will be
downloaded by the reviewers and publisher.
Please see the sections below for instruc-
tions regarding Figure and Table files.
Once the paper has been accepted for
publication, and final versions of the
manuscript, figures, and table files have
been uploaded to the Editorial Manager
interface, PDF files will not be used for
typesetting. This is important to note for
Table and Figure files, which may lose
formatting when converted to PDF, but will
remain intact in their original file format.
Title Page
A title page must be included in the
manuscript file. Include on the title page: a)
complete manuscript title; b) authors’ full
names, academic degrees, and affiliations;
c) name and address for correspondence,
including fax number, telephone number,
and e-mail address; d) address for reprints
if different from that of corresponding
author; e) meetings at which parts of the
data were presented (including title of
conference, city, and date); f) sources of
support; and g) a running head of no more
than 40 characters.
The title page must also include
disclosure of funding received for this work
from any of the following organizations:
National Institutes of Health (NIH);
Article type Limitations Abstracts
Original Articles
(including
Implementation
and Operational
Research)
3500 words + 5 ﬁgures/
tables – if more
then use Supplemental
Digital Content
Structured, 250 words
Rapid Communications 2000 words + 2 ﬁgures/tables Unstructured, 150 words
Critical Reviews 3000 words + 2 ﬁgures/tables Unstructured; 150 words
Brief Reports 2000 words + 2 ﬁgures/tables Unstructured; 100 words
Letter to the Editor 1500 words; 1 ﬁgure/table Publish online only
Article types are described in a separate section further in instructions.
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Wellcome Trust; Howard Hughes Medical
Institute (HHMI); and other(s).
Abstract and Key Words
The abstract should be structured and
limited to 250 words depending on article
type. It must be factual and comprehensive.
Limit the use of abbreviations and acro-
nyms, and avoid general statements (eg, ‘‘the
significance of the results is discussed’’).
List 3 to 6 key words or phrases.
Text
Organize the manuscript file into
sections with appropriate section headings.
The sequence should be as follows: title
page, abstract/key word page, introduction,
methods, results, discussions, acknowledg-
ments, references, tables, figures and figure
captions.
Authors should type, whenever pos-
sible, all mathematical and chemical sym-
bols, equations, and formulas, and identify
all unusual symbols the first time they are
used. Define abbreviations at first mention
in text and in each table and figure. If a
brand name is cited, supply themanufacturer’s
name and address (city and state/country).
Abbreviations
For a list of standard abbreviations,
consult the Council of Biology Editors
Style Guide (available from the Council of
Science Editors, 9650 Rockville Pike,
Bethesda, MD 20814) or other standard
sources. Write out the full term for each
abbreviation at its first use unless it is a
standard unit of measure.
References
The authors are responsible for the
accuracy of the references. Key the refer-
ences (double-spaced) at the end of the
manuscript. (If using End Note, set the style
output to JAMA.) Cite references in text in
order of appearance. Cite unpublished data,
such as papers submitted but not yet
accepted for publication, or personal com-
munications, in parentheses in the text. If
there are more than 3 authors, list only the
first 3 authors and then use et al. Refer to the
List of Journals Indexed in Index Medicus
for abbreviations of journal names. Sample
references are given below:
Journal Article
1. Schambelan M, Benson CA, Carr A,
et al. Management of metabolic com-
plications associated with antiretroviral
therapy for HIV-1 infection: recommen-
dations of an International AIDS Soci-
ety-USA panel. J Acquir Immune Defic
Syndr. 2002;31:257–275.
Book Chapter
2. Wortmann RL, Bentzel CJ. Renal
handling of uric acid. In: Massry SG,
Glassock RJ, eds. Massry and Glass-
ock’s Textbook of Nephrology. Phiadel-
phia: Lippincott Williams & Wilkins,
2001;90–92.
Entire Book
3. Mandell GL, Mildvan D, eds. Atlas of
AIDS. 3rd ed. Philadelphia: Lippincott
Williams & Wilkins; 2001.
Software
4. Epi Info [computer program]. Version 6.
Atlanta: Centers for Disease Control and
Prevention, 1994.
Online Journals
5. Friedman SA. Preeclampsia: a revi w of
the role of prostaglandins. Obstet Gyne-
col [serial online]. January 1988;71:22–
37. Available from: BRS Information
Technologies, McLean, VA. Accessed
December 15, 1990.
Database
6. CANCERNET-PDQ [database online].
Bethesda, MD: National Cancer Insti-
tute, 1996. Updated March 29, 1996.
World Wide Web
7. Panel on Clinical Practices for the
Treatment of HIV Infection. Guidelines
for the use of antiretroviral agents in
HIV-infected adults and adolescents.
Department of Health and Human
Services and Henry J. Kaiser Founda-
tion, January 28, 2000. Available at:
http://www.hivatis.org/
guidelines/AA599.pdf.
Paper Presented at a Conference
8. Koenig L, Ellerbrock T, Pratt-Palmire M,
et al. Prospective predictors of medication
adherence: a study of the first six months
of highly active antiretroviral therapy
(HAART) using electronic monitoring
[WePeB5818]. Presented at: XIV Interna-
tional AIDSConference; 2002; Barcelona.
Figures
Cite figures consecutively in the text,
and number them in the order in which they
are discussed. Submit all artwork in
camera-ready form through Editorial
Manager; illustrations should be glossy
prints or high-quality, laser-printed illus-
trations. Photocopies are unacceptable.
Authors must submit figures as separate
electronic files. High-quality hard copies
may be requested once the manuscript has
been accepted for publication. Lettering
should be large enough that it will remain
legible after figure reduction; typewritten
or unprofessional lettering is unacceptable.
Figure parts (A, B, C) may be left unlabeled
(but clearly marked on back) for profes-
sional placement by the journal’s printer.
Figure Legends
Legends must be submitted for all
figures. They should be included in the
manuscript file, should be brief and speci-
fic, and should appear on a separate manu-
script page after the references. Use scale
markers in the image for electron micro-
graphs, and indicate the type of stain used.
Color Figures
The journal accepts for publication
color figures that will enhance an article.
Authors who submit color figures will
receive an estimate of the cost for color
reproduction. If they decide not to pay for
color reproduction, they can request that
the figures be converted to black and white
at no charge.
Digital Figures
Electronic art should be created/
scanned and saved and submitted as either
a TIFF (tagged image file format), an EPS
(encapsulated postscript) file, or a PPT
(Power Point) file. Line art must have a
resolution of at least 1200 dpi (dots per
inch), and electronic photographs—radio-
graphs, CT scans, and so on—and scanned
images must have a resolution of at least
300 dpi. If fonts are used in the artwork,
they must be converted to paths or outlines
or they must be embedded in the files.
Color images must be created/scanned and
submitted as CMYK files. Files should be
submitted electronically through the Edi-
torial Manager interface. Please note that
artwork generated from office suite pro-
grams such as Corel Draw and MS Word
and artwork downloaded from the Internet
(JPEG or GIFF files) cannot be used. PDF
files will also not be accepted.
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Supplemental Digital Content (SDC)
Authors may submit SDC via Edi-
torial Manager to LWW journals that
enhance their article’s text to be considered
for online posting. SDC may include
standard media such as text documents,
graphs, audio, video, etc. On the Attach
Files page of the submission process,
please select Supplemental Audio, Video,
or Data for your uploaded file as the
Submission Item. If an article with SDC is
accepted, our production staff will create a
URL with the SDC file. The URL will be
placed in the call-out within the article.
SDC files are not copy-edited by LWW
staff, they will be presented digitally as
submitted. For a list of all available file
types and detailed instructions, please visit
http://links.lww.com/A142.
SDC Call-outs
Supplemental Digital Content must
be cited consecutively in the text of the
submitted manuscript. Citations should
include the type of material submitted
(Audio, Figure, Table, etc.), be clearly
labeled as ‘‘Supplemental Digital Con-
tent,’’ include the sequential list number,
and provide a description of the supple-
mental content. All descriptive text should
be included in the call-out as it will not
appear elsewhere in the article.
Example:
We performed many tests on the
degrees of flexibility in the elbow (see
Video, Supplemental Digital Content 1,
which demonstrates elbow flexibility) and
found our results inconclusive.
List of Supplemental Digital Content
A listing of Supplemental Digital
Content must be submitted at the end of the
manuscript file. Include the SDC number
and file type of the Supplemental Digital
Content. This text will be removed by our
production staff and not be published.
Example:
Supplemental Digital Content 1.
wmv
SDC File Requirements
All acceptable file types are permis-
sible up to 10 MBs. For audio or video files
greater than 10 MBs, authors should first
query the journal office for approval. For a
list of all available file types and detailed
instructions, please visit http://links.lww.
com/A142. Please do not submit pdfs.
Tables
Create tables using the table creating
and editing feature of your word-process-
ing software (eg, Word, Word-Perfect). Do
not use Excel or comparable spreadsheet
programs. Group all tables together and
upload them in a separate file. Cite tables
consecutively in the text, and number them
in that order. Key each on a separate sheet,
and include the table title, appropriate
column heads, and explanatory legends
(including definitions of any abbreviations
used). Do not embed tables within the body
of the manuscript. They should be self-
explanatory and should supplement, rather
than duplicate, the material in the text.
Style
Pattern manuscript style after the
American Medical Association Manual of
Style (9th edition). Stedman’s Medical
Dictionary (28th edition) and Merriam-
Webster’s Collegiate Dictionary (11th edi-
tion) should be used as standard references.
Refer to drugs and therapeutic agents by
their accepted generic or chemical names,
and do not abbreviate them. Use code
numbers only when a generic name is not
yet available. In that case, supply the
chemical name and a figure giving the
chemical structure of the drug. Capitalize
the trade names of drugs and place them in
parentheses after the generic names. To
comply with trademark law, include the
name and location (city and state in USA;
city and country outside USA) of the
manufacturer of any drug, supply, or
equipment mentioned in the manuscript.
Use the metric system to express units of
measure and degrees Celsius to express
temperatures, and use SI units rather than
conventional units.
Obligation to Register Clinical
Trials
JAIDS has adopted the standards of
the International Committee of Medical
Journal Editors with regard to the registra-
tion of clinical trials. As a condition of
consideration for publication, data from
research projects ‘‘prospectively assigning
human subjects to intervention or concur-
rent comparison or control groups to study
the cause-and-effect relationship between a
medical intervention and a health out-
come’’ must be registered in a public trials
registry. The Protocol Registration System
(http://prsinfo.clinicaltrials.gov/) offered
through the U.S. National Institutes of
Health is one such registry.
GenBank Accession Numbers
When manuscripts include or de-
scribe original nucleotide or amino acid
sequence data, the sequence must be
submitted to the GenBank/EMBL/DDBJ
sequence database and an accession num-
ber obtained from them. This accession
number must be returned to the journal,
where it will be placed after the Key Words
on the title page in the printed article.
URLs for the 3 members of the Interna-
tional Nucleotide Sequence Database Col-
laboration (GenBank/EMBL/DDBJ) are as
follows (respectively): http://www.ncbi.
nlm.nih.gov/BankIt/, http://www.ebi.ac.uk/
embl/, http://www.ddbj.nig.ac.jp/.
ARTICLE TYPES
Original Articles
The above guidelines apply to the
original article format. Articles should be
limited to 3500 words + 5 figures/tables.
If additional space is needed, then use
Supplemental Digital Content options.
There should be a structured abstract of
250 words or less.
Implementation and Operational
Research (NEWARTICLE TYPE)
JAIDS is now accepting manuscripts
for a new focus area of interest: Imple-
mentation and Operational Research. In the
context of HIV/AIDS with advances in
HIV therapy and care, expansion of global
access to treatment, care and prevention
Implementation and Operational Research,
while having particular relevance to global
health is an important domestic focus as
well. However the lessons learned through
this research discipline are particularly
relevant to guiding best practices in low-
resource settings as antiretroviral drug
access is expanded. Articles that encom-
pass the translation of knowledge, practi-
ces, and technologies into clinical care of
adult and pediatric patients with HIV/AIDS
and their evidence-based effectiveness in
‘‘real world settings’’ are of particular
interest.
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All manuscripts should be submitted
through one of the existing three sections:
Basic and Translational Science, Clinical
Science, or Epidemiology and Prevention
using the article type Implementation and
Operational Research. Structure of article
is the same as Original Article.
If accepted for publication, articles
are published ONLINE ONLY with titles
appearing in the print and online edition
table of contents.
Rapid Communications
Articles accepted as Rapid Commu-
nications will normally be published within
8 weeks of acceptance. When submitting a
paper for consideration as a Rapid Com-
munication, please adhere to the following
guidelines:
 Submit your paper to Editorial Man-
ager and designate the article type as
‘‘Rapid Communication.’’ Please in-
dicate to the Editor in a cover letter file
why the paper merits special attention.
 The paper should not exceed 2000
words and 2 figures/tables.
 The paper should include an unstruc-
tured abstract (150 words or less), key
words, methods, results, discussion,
and reference sections.
 The title page should include the
corresponding author’s telephone and
fax numbers and e-mail address.
 Authors will receive proofs of their
article for review by e-mail and will be
expected to return corrections by fax
within 24 hours of receipt. Changes
received after this deadline will not be
accepted.
Papers that are not accepted as Rapid
Communications may be considered as
full-length articles.
Critical Reviews
Papers reviewing the literature on a
particularly timely and interesting topic
will be considered for publication in
JAIDS. Authors are encouraged to keep
review articles to less than 3000 words and
2 figures/tables with an unstructured
abstract of 150 words or less. In general,
review articles written as work-for-hire by
industry employees will not be considered
for publication. All funding, writing assis-
tance, and other relationships to possibly
conflicted sources must be fully disclosed
at the time of submission.
Brief Reports
Brief Reports are short versions of
clinical studies. They represent observa-
tions that are preliminary, speak for
themselves, or offer new insight into a
recognized condition. Submissions should
not exceed 2000 words + 2 figures/tables
with an unstructured abstract of 100 words
or less.
Letters to the Editor
Letters to the Editor can provide
additional comment on an article published
in JAIDS, or can be a very concise report on
study findings. Letters should be no more
than 1500 words and 1 figure/table.
Beginning with July 15, 2010 submis-
sions, Letters to the Editor will be
published ONLINE ONLY. Title will
appear in print and online edition table of
contents.
Page Proofs and Corrections
PDF files of the copyedited, typeset
pages and support documents (eg, reprint
order form) will be sent to the correspond-
ing author via e-mail. Complete instruc-
tions will be provided with the e-mail for
downloading and printing the files and for
faxing the corrected pages to the publisher.
It is the author’s responsibility to ensure
that there are no errors in the proofs.
Changes that have been made to conform
to journal style should be allowed to stand
if they do not alter the authors’ meaning.
Only critical changes improving the accu-
racy of the content will be made. Changes
that are stylistic or are a reworking of
previously accepted material will not be
allowed. The publisher reserves the right to
deny any changes that do not affect the
accuracy of the content. Authors may be
charged for alterations to the proofs beyond
those required to correct errors or to answer
queries. Proofs must be checked carefully
and corrections faxed within 24 to 48 hours
of receipt, as requested in the cover letter
accompanying the page proofs.
Reprints
Reprint orders should be submitted to
the Reprints Department (1-800-341-2258
or reprintsgroup@LWW.com). Payment for
reprints or a purchase order number must
accompany your order form. Orders without
these cannot be fulfilled. More information
can be obtained at http://www.lww.com/
periodicals/author-reprints/
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Authorship Responsibility, Financial Disclosure, and Copyright Transfer 
 
Manuscript Title:           ,including all 
accompanying digital supplementary content, if any(the “Work”) 
Corresponding Author:  
Mailing Address and Telephone/Fax Numbers:  
 
Each author must read and sign the following statements; if necessary, photocopy this document and distribute to coauthors 
for their original ink signatures. Completed forms must be submitted to the Editorial Office with the Work. In the event an 
author is unable to supply their ink signature at the time of submission, the Corresponding Author should indicate in the Cover 
Letter that the missing signature(s) will be forthcoming and subsequently submit them via email directly and collectively to the 
Editorial Office: Basic and Translational Science articles: c/o Denise Gottwald, DGottwal@adarc.org. Clinical Science 
articles: c/o Terry O’Donnell, jaids@chi.ucsf.edu. Epidemiology and Prevention articles: c/o Claire Edelen, 
CEdelen@som.umaryland.edu. 
 
CONDITIONS OF SUBMISSION 
RETAINED RIGHTS: Except for copyright, other proprietary rights related to the Work (e.g., patent or other rights to any 
process or procedure) shall be retained by the authors. To reproduce any text, figures, tables, or illustrations from this Work in 
future works of their own, the authors must obtain written permission from Lippincott Williams & Wilkins (LWW); such 
permission cannot be unreasonably withheld by LWW. 
ORIGINALITY: Each author warrants that his or her submission to the Work is original and that he or she has full power to 
enter into this agreement. Neither this Work nor a similar work has been published nor shall be submitted for publication 
elsewhere while under consideration by this Publication. 
AUTHORSHIP RESPONSIBILITY: Each author warrants that he or she has participated sufficiently in the intellectual content, 
the analysis of data, if applicable, and the writing of the Work to take public responsibility for it. Each has reviewed the final 
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Figure 1. Flow diagram of study participants. 
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Figure 2 A. Scatter plots with regression slopes for venous and capillary 
samples  
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Figure 2B. Bland Altman Plots 
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